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ABSTRACT 
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are severe 
X-linked recessive, degenerative neuromuscular diseases. DMD/BMD are caused by 
deletions, duplications and point mutations in the DMD gene situated on the X-
chromosome. Studies have shown that the risk of being a carrier for DMD/BMD has a 
psychosocial impact on individuals and affects their requests for DNA testing and their 
choices regarding reproduction. Very few articles have been published to date and this 
study is the first South African study to investigate the behaviours of individuals in 
DMD/BMD families. 
 
The study aimed to investigate why individuals attended genetic counselling and who 
referred them.  It also aimed to identify factors that influence at-risk individuals‟ decisions 
regarding genetic counselling, carrier testing and reproduction.  The study was 
retrospective and data were obtained by reviewing genetic counselling files at the Division 
of Human Genetics, National Health Laboratory Service and the University of the 
Witwatersrand.  The sample consisted of 79 files of families seen for genetic counselling 
regarding DMD/BMD from 1995 to 2008. Subjects included the maternal female relatives 
of affected individuals, who were all of reproductive age (15-49 years); the total number of 
at-risk individuals identified was 237. 
 
Subjects were divided into three groups according to their assigned reproductive risks: low 
(0-9%), intermediate (10-24%) and high (>25%). The influence of reproductive risk and 
other identified variables on decisions to attend genetic counselling, have carrier testing 
and having children were analysed using chi-squared and logistic regression analysis. 
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Reproductive risk and relationship to the affected individuals were shown to be significant 
predictors of individuals‟ decisions.  Other factors that contributed significantly to the 
behaviour of at-risk individuals were ethnicity, age, whether a mutation was de novo and 
whether an individual had affected children. 
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1.0 INTRODUCTION 
 
Duchenne Muscular Dystrophy (DMD), previously also known as Meryon‟s disease as it 
was first discovered and described by Edward Meryon, an English physician, in 1951.  
However, it was Duchenne de Boulogne, a French physician, who was credited with the 
discovery of the disease after he described it in detail in the 1960s (Emery, 2001).   
 
Becker Muscular Dystrophy (BMD) was first described in 1934, but it was Professor P.E. 
Becker, a German geneticist, who first described BMD as „a new X-chromosomal 
muscular dystrophy‟ (Emery, 2001, p.72).  In 1955, he also noted that the severity of BMD 
differed from that of DMD but he speculated that the two diseases were possibly caused by 
mutations in the same allele (Emery, 2001).  This was later confirmed and today it is well-
known that DMD and BMD are distinct phenotypes that result from different mutations 
within the same gene.  
 
1.1 Duchenne and Becker Muscular Dystrophy 
DMD is a severe X-linked recessive, degenerative neuromuscular disease with an 
incidence of 1 in 3,500 live male births.  BMD is a milder form of DMD with an incidence 
of 1 in every 18,000 live male births (Gatta et al., 2005). However, a South African study 
on 143 DMD patients showed a low prevalence (1 in 250,000) of DMD in the Black 
population compared to the international prevalence (Ballo, Viljoen & Beighton, 1994). 
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1.1.1 Clinical Presentation 
DMD presents in early childhood with delayed milestones in sitting, independent standing 
and walking.  Characteristic proximal weakness of the muscles causes toe walking, a 
waddling gait and difficulty in climbing.  The progression of DMD is rapid and individuals 
are usually wheelchair bound by the age of 12 years (Emery, 2001).  Cardiomyopathy 
occurs in all individuals with DMD after 18 years of age and scoliosis occurs in 90% of 
DMD affected individuals (Firth & Hurst, 2005).  The common causes of death are 
respiratory failure and cardiomyopathy before the third decade of life (Emery, 2001).  
 
BMD presents at a mean age of 11 years with difficulty in walking and running with 
frequent falling (Firth & Hurst, 2005; Emery, 2001).  The clinical features of BMD can be 
variable and wheelchair dependency can range from 12 to 70 years with varying degrees of 
disease progression.  As with DMD, proximal muscle weakness and cardiomyopathy 
occur.  The mean age of death in BMD affected individuals is mid-forties, with dilated 
cardiomyopathy being the main cause of death (Emery, 2001).  
 
1.1.2 Pathogenesis of DMD/BMD 
DMD/BMD is caused by mutations in the DMD gene situated at Xq21.2.  The DMD gene 
produces the dystrophin protein and is the largest human gene discovered to date, with 79 
exons (Gatta et al., 2005). The size of the DMD gene constitutes 0.1% of the total human 
genome and 1.5% of the X-chromosome (Muntoni, Torelli & Ferlini, 2003).   
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Dystrophin is mainly expressed in cardiac and skeletal muscle cells and to a lesser extent 
in the brain.  Dystrophin interacts with membrane proteins in the sarcolemma of the 
muscle cells; together these proteins form the dystrophin-glycoprotein complex (Figure 
1.1).   
 
 
 
 
 
 
 
 
 
This complex plays an important structural role in muscle cells and also protects the 
muscle fibres from damage and death that may result from regular muscle contractions.  
The dystrophin-glycoprotein complex also plays an important role in cell signalling across 
membranes (Muntoni et al., 2003).  Mutations in the DMD gene therefore affect the 
functionality of the dystrophin protein. 
 
Figure 1.1: The dystrophin-glycoprotein complex 
(Khurana & Davies, 2003)  
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1.1.3 Genetics of Duchenne and Becker Muscular Dystrophies 
1.1.3.1 Mode of Inheritance  
DMD and BMD are single gene disorders that affect all ethnic groups similarly and are 
both inherited in an X-linked recessive manner.  Females are unaffected carriers of the 
condition because of the normal, compensatory gene on their second X-chromosome.  A 
female carrier has a 50% chance of passing on the X-chromosome with the DMD mutation 
to her offspring.  Males who inherit the mutation present with the condition as they only 
have one X-chromosome.  Females who inherit the mutation will be unaffected carriers.  A 
DMD mutation can either be familial or as a result of a de novo mutation.  
 
1.1.3.2 De novo mutations  
A de novo DMD mutation is either caused by an event that occurred in the grandparental 
germline or the maternal germline of an affected individual.  De novo point mutations are 
more often inherited from the maternal grandfather whereas deletions are more often 
inherited from the maternal grandmother (Helderman-van den Enden et al., 2009).  Based 
on the assumption that males and females have equal mutation rates, it was predicted that 
one third of all DMD/BMD cases are due to de novo mutations (Morton and Lalouel 
(1979) cited in (Danieli & Barbujani, 1984)).  It is thought that the DMD gene has a higher 
mutation rate than the average rate for other human genes because of its enormous size 
(Aartsma-Rus, Van Deutekom, Fokkema, Van Ommen & Den Dunnen, 2006).   
 
1.1.3.3 Mutation types 
Mutations responsible for DMD are mostly nonsense or frame-shift mutations that result in 
barely detectable, truncated protein products, whereas mutations that cause BMD are 
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mostly in-frame and result in the production of less but partly functional dystrophin (Firth 
& Hurst, 2005; Muntoni et al., 2003).  This „reading-frame model‟ first presented by 
Monaco, Bertelson, Liechti-Gallati, Moser and Kunkel (1988) still holds true and is 90% 
accurate in determining whether an individual has the DMD or BMD phenotype (Muntoni 
et al., 2003; Monaco et al., 1988).  
 
Large deletions in the DMD gene are the major cause of DMD/BMD and account for 65% 
of DMD cases and 85% of BMD cases.  Other DMD gene mutations include point 
mutations and duplications (Table 1.1) (Darras, Korf & Urion, 2008; Gatta et al., 2005).   
 
Table 1.1: DMD/BMD causing mutations. 
 DMD BMD 
Large deletions ~65% ~85% 
Duplications ~5-10% ~5-10% 
Point mutations ~25-30% ~5-10% 
 
Most of the mutations occur in two defined hotspot regions, which include exons 2-19 and 
44-55 (Muntoni et al., 2003).   Modern day molecular techniques are sensitive and 
advanced, and can detect all the different types of mutations.  
 
1.1.4 Diagnostic testing for confirmation of DMD/BMD in affected individuals 
In South Africa, DMD/BMD is first diagnosed by the clinical history and physical 
examination of an affected individual.  The serum creatine phosphokinase concentration is 
evaluated and confirmation of the diagnosis is made with molecular genetic testing.  If no 
deletion or duplication is detected, the diagnosis can be confirmed by sequencing of the 
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DMD gene or by muscle biopsy to measure the amount of dystrophin in the muscle fibres.  
The diagnostic tests are elaborated below.    
 
1.1.4.1 Serum Creatine Phosphokinase concentration 
The first step in the diagnosis of DMD/BMD after clinical evaluation is the determination 
of serum creatine kinase (CK) levels, also known as creatine phosphokinase (CPK). CK is 
an enzyme that assists with the release of energy from creatine in the body and is mainly 
present in cells with high energy requirements, primarily the brain, thyroid, skeletal and 
heart muscles (Martin, 2007).  DMD/BMD individuals have increased serum CK levels as 
a result of leakage from damaged muscle fibers (Ozawa, Hagiwara & Yoshida, 1999) and 
are elevated to more than ten times the normal value in DMD individuals and five times in 
BMD individuals (Darras et al., 2008).  
 
1.1.4.2 Genetic testing 
Multiplex polymerase chain reaction (PCR) and Southern Blotting techniques have been 
the two commonly used molecular techniques to screen for DMD mutations.  Multiplex 
PCR is a method that simultaneously amplifies the exons 2-20 and 42-53 which includes 
the two hotspot regions.  Almost all the DMD/BMD deletions are situated in these hotspot 
regions.  The multiplex PCR method can detect 98% of „hotspot‟ deletions in affected 
males (Gatta et al., 2005; van Essen et al., 1997).  However, multiplex PCR does not detect 
duplications and southern blotting is therefore used as a complimentary method.  Southern 
blotting is a technique used to detect deletions and duplications by using cDNA probes to 
detect the site of mutations along the entire DMD gene (Prior & Bridgeman, 2005).   
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Two of the newer techniques used are the Multiplex Ligation-Dependent Probe 
Amplification (MLPA) and gene sequencing techniques.  The MLPA method is a more 
rapid and efficient technique and can be used to screen for deletions and duplications in all 
79 exons of the DMD gene (Gatta et al., 2005).  Gene sequencing detects small mutations 
generally not detected with the other available techniques.  These mutations include: 
deletions, duplications, single-base changes, and splicing mutations (Darras et al., 2008). 
 
In South Africa in 1987, the first screening service for carrier detection and prenatal 
diagnosis was started at the Department of Human Genetics, University of Cape Town 
(Ballo, Hitzeroth & Beighton, 1991).  Up to 2007, deletion screening to confirm the 
diagnosis of DMD/BMD was routinely offered.  The multiplex PCR method was used to 
test for common deletions in the following exons 2-4,6,9,11-13,16,17,19,25,32,34,41-
52,60 and 66.   In 2008, a newer and more effective MLPA test was offered to screen for 
deletions and duplications in the DMD gene.  It is not yet possible to detect point mutations 
at the Division of Human Genetics, NHLS/WITS or any other laboratory in South Africa 
and samples with suspected point mutations or other small mutations can be sent overseas 
for sequencing analysis of the full DMD gene.  However, this option is only available to 
patients who can afford this testing.   
 
1.1.4.3 Muscle biopsy  
Muscle biopsy is not the preferred method for testing because it is an invasive test.  A 
muscle biopsy followed by Western Blotting or Immunohistochemical staining of 
dystrophin however, is an accurate technique to confirm the clinical diagnosis of DMD/ 
BMD.  Dystrophin levels are nearly depleted in muscle biopsies from DMD affected 
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individuals whereas in BMD, affected individuals can have dystrophin levels between 20 
and 50% in their muscle tissue (Darras et al., 2008).  In the situation where genetic testing 
failed to detect a gene mutation, a muscle biopsy can be performed to confirm a diagnosis 
of DMD/BMD.  
 
1.2 Genetic Counselling 
Genetic counselling is an essential service for individuals affected with, or at-risk of being 
carriers of DMD/BMD.  Genetic counselling is a holistic service that offers medical 
information, psychosocial support and continued management to individuals and families.  
Genetic counselling is defined by the National Society of Genetic Counselors (NSGC) as:  
“Genetic Counseling is the process of helping people understand and adapt to the medical, 
psychological, and familial implications of the genetic contributions to disease. This 
process integrates: 
• Interpretation of family and medical histories to assess the chance of disease 
occurrence or recurrence. 
• Education about inheritance, testing, management, prevention, resources and 
research. 
• Counseling to promote informed choices and adaptation to the risk or condition” 
(Resta et al., 2006). 
Although the primary aim of genetic counselling is to inform individuals about their risks, 
helping them understand their risks and assisting them in making informed decisions, the 
genetic counselling consultation involves both counselling and testing services (Smerecnik, 
Mesters, Verweij, de Vries & de Vries, 2009).   
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DMD and BMD are incurable, disabling conditions and lead to premature demise.  The 
female relatives, including the mothers, sisters, nieces, aunts, cousins and daughters (of 
BMD individuals) therefore request genetic counselling and carrier testing to get an 
indication of the risk that their offspring will be affected with the conditions (van Essen et 
al., 1997). 
 
1.2.1 The family pedigree  
Pedigree construction is an inexpensive, reliable and non-invasive method of obtaining 
family information (Wolpert & Speer, 2005).  A pedigree is usually constructed as a three 
generation family tree with information on different diseases or genetic conditions in a 
family, the age of disease onset, death, age and causes of the deaths.  This information 
should be obtained for first, second and third degree relatives but generally the information 
gets less accurate with an increase in the distance of relatedness (Wattendorf & Hadley, 
2005).  The family pedigree is useful in that it gives an indication of biological 
relationships in the family.  It is important to keep in mind that families and the 
information around individuals in a family constantly change, and it is therefore important 
to update the family pedigree regularly (Wolpert & Speer, 2005). 
 
Constructing a pedigree is useful in genetic counselling because it serves as a tool to assist 
in the diagnosis of a condition, the inheritance pattern and in calculating risks of 
individuals to either carry a mutation or develop a condition.  With pedigree construction, 
an added benefit is the psychosocial information that is often revealed, which can be used 
in establishing a counsellor-client relationship (Veach, LeRoy & Bartels, 2003).  In genetic 
counselling the information obtained with a family pedigree can be used to provide 
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information about reproductive risks and can also function in the early diagnosis and 
management of certain conditions.   
 
The pedigree can also be used as a tool when informing individuals about their risk.  The 
pedigree provides the necessary framework to help individuals understand their risks and 
the risks to their offspring (Smerecnik et al., 2009). 
 
1.2.2 Risk perception 
Risk plays an important role in genetic counselling; it is essential to present risk 
information accurately, thus allowing individuals to make informed decisions based on 
their perception of their risks (Smerecnik et al., 2009; Parsons & Clarke, 1993).  In genetic 
counselling, individuals are given a mathematical number for their risk but it has been 
shown that individuals have difficulty in understanding and perceiving their risk when 
presented in a numerical way (Sivell et al., 2008).  However, Sivell, et al. (2008) and 
Smerecnik, et al. (2009) performed systematic reviews and found that individuals‟ 
accuracy of their risk perception improved with genetic counselling. 
 
It is not only the perception of risk that influences decisions; the burden of the disease has 
also been shown to have an influence on the individual‟s decisions (Smerecnik et al., 
2009).  Other factors that contribute to complicated decision-making are an individual‟s 
coping mechanisms, worry and anxiety about the implications of their risk (Smerecnik et 
al., 2009),  previous experiences, environmental factors, profession, diet and other genetic 
or family history factors (Sivell et al., 2008).  All these factors combined and considered 
will impact on the individual‟s ability to make a decision appropriate to them. 
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Even with the different contributing factors influencing decision-making, it is still crucial 
to give accurate risks as this is the primary foundation of informed decision-making.  
Bayes‟ theorem is commonly used in genetic counselling to calculate accurate risks.  The 
theorem calculates the prior probability that an individual carries the disease causing 
mutation and then adapts that probability with new information that becomes available, 
e.g. test results or the birth of healthy children.   In essence, the theorem continually uses 
information that becomes available and then combines the probabilities that an event will 
arise or not (Turnpenny, Ellard & Emery, 2007).  This is useful because carrier risk is not 
definitive and can change as more genetic information on the family becomes available 
(Parsons & Clarke, 1993). 
 
1.2.3 Carrier testing for at-risk individuals 
Testing individuals at-risk of carrying a DMD mutation is considered important because it 
can assist in refining risks, informed decision making and clarify prenatal options.  Before 
testing an at-risk individual, testing of the DMD/BMD affected individual needs to be 
done.  It is not always possible to detect the disease causing mutation in an affected 
individual.  It is also not always possible to test an affected individual for the family 
mutation because of reticence, geographical distance, or death of the affected individual.   
 
1.2.3.1 Testing options 
 In families with a known mutation 
The multiplex-PCR or MLPA methods can be used for carrier detection where the family 
mutation in the DMD gene is known.  For point mutations, DMD gene sequencing can be 
performed on the specific gene section for detection of the mutation. 
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 In families without a known mutation 
The most commonly used method when the family mutation is unknown, is linked marker 
analysis for carrier detection.  DMD intragenic polymorphic markers are used to detect the 
presence of the high risk X-chromosome.  This method is limited however, by the number 
of informative markers in the DMD gene and in families with a single affected male. 
 
 In families with no proband 
In families with no available proband, the preferred method of defining risk is linked 
marker analysis to try and track the high-risk X chromosome in the family.  Healthy 
unaffected brothers of the proband can be useful as they will always have the low-risk X 
chromosome.  
 
1.2.4 Prenatal Diagnosis 
Prenatal diagnosis is offered to women with a family history of DMD/BMD and to women 
with an increased risk of germline mosaicism as a result of a de novo event.  A de novo 
event is assumed where there is no family history of DMD/BMD and the affected 
individual is the first one in the family. The first step in prenatal diagnosis is to determine 
the gender of the fetus by invasive testing or ultrasound examination. This would be 
followed with molecular testing for the disease causing mutation, in a male fetus.  Female 
fetuses are not tested for the DMD mutation because they are not at risk of being affected 
with the condition but rather at 50% risk of being unaffected carriers.   
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The two invasive techniques routinely used for prenatal diagnosis are chorionic villi 
sampling (CVS), a technique used to obtain chorionic villi (placental tissue) between 10 
and 13 weeks gestation, and amniocentesis, where amniocytes present in the amniotic fluid 
are extracted, cultured and analysed.  Amniocentesis is a second trimester test, ideally 
performed between 16-22 weeks of pregnancy.  Both procedures have a risk for 
miscarriage. Linkage analysis or molecular testing can now be performed on the chorionic 
villi sample or the cultured fetal cells from the amniotic fluid to confirm the presence or 
absence of the high risk X-chromosome or DMD mutation in the fetus.   
 
DMD/BMD are fatal conditions with no successful curative therapeutic interventions to 
date (Scime & Rudnicki, 2008).  The options for parents once a positive result is obtained 
in a fetus, are either to terminate the pregnancy or to keep the affected baby.  CVS offers 
an early result and a termination of pregnancy at an early stage in pregnancy can be less 
traumatic physically.  A termination of pregnancy in the second trimester can be more 
traumatic because of experienced fetal movement and a longer time period for maternal 
bonding with the baby.    
 
1.3 Psychosocial aspects of being a carrier of a genetic disease 
A qualitative study by Williams and Schutte (1997) of 34 at-risk individuals showed that 
after genetic testing, non-carriers experienced relief from the burden of fear and also 
expressed freedom to continue with their reproductive planning.  However, carriers 
experienced feelings of sadness, as well as the loss of hope to have unaffected children and 
grandchildren. Interestingly, it was found that both carriers and non-carriers had difficulty 
informing family members of their genetic status. Carriers that already had affected 
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children did not experience any reassurance after receiving confirmation of their carrier 
status (Williams & Schutte, 1997).  
 
Mothers of children with an X-linked condition, when they are confirmed as carriers, 
experience more guilt and blame, and feel more stigmatised because of their carrier status 
compared to parents of children with autosomal recessive diseases (James, Hadley, 
Holtzman & Winkelstein, 2006). Guilt experienced by the mothers of affected children can 
easily turn into depression with feelings of hopelessness and helplessness. Fathers of 
children with X-linked diseases are more likely to blame their partners than those with 
children with autosomal recessive diseases (James et al., 2006). 
 
A study by Marteau, van Duijn, and Ellis (1992) on the effect of genetic screening on a 
group of individuals at risk of being carriers for a recessive disease, found that carriers are 
less optimistic about their future health than non-carriers.  The authors suggested that 
confirmation of carrier status might have a subtle influence on an individual‟s self-
perception (Marteau et al., 1992).   
 
1.4 Behaviour of at-risk individuals  
At-risk individuals base their decisions both on the cognitive and emotional considerations 
and their decisions may not always seem logical to medical professionals (Decruyenaere, 
Evers-Kiebooms, Denayer & Welkenhuysen, 1998). 
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1.4.1 Decision to undergo carrier testing 
Prior to genetic testing, at-risk individuals experience fear; fear to have an affected child, 
fear that carrier children can pass the gene on to the next generation and fear that the 
results will prove their belief that they are responsible for transferring the gene to their 
offspring (Williams & Schutte, 1997).  
 
To make a decision is difficult and naturally a number of factors play a role in this process.  
The individuals‟ perceived risk plays a major role in their desire to take up carrier testing 
(Decruyenaere et al., 1998).  A systematic review, focussing on published quantitative 
surveys and qualitative research, on cystic fibrosis (CF) carrier testing identified factors 
that would affect decisions.  CF is a debilitating recessive genetic condition marked by the 
build-up of thick, sticky mucus in the lungs and digestive tract which is responsible for 
chronic lung disease, pancreatic insufficiency and a shortened life-span.  Three factors that 
strongly influenced decisions to undergo CF carrier testing were the perceived benefits of 
testing, the perceived barriers to carrier testing and having/desiring children (Chen & 
Goodson, 2007).  A review on retrospective, descriptive studies showed that the benefits 
most recognized by individuals are knowing one‟s carrier status and preventing affected 
children (Decruyenaere et al., 1998).  Individuals who perceived carrier testing as 
beneficial are more likely to undertake testing.  A perceived barrier to testing is the thought 
about attached stigma.  Individuals who do not perceive stigma as negative are more likely 
to be tested.  Individuals with a strong desire to have children, are twice as likely to have 
carrier testing than individuals with weaker intentions to have children (Chen & Goodson, 
2007).  Interestingly, at-risk individuals with unaffected children are less likely to have 
carrier testing possibly because of their perception that they are at a lower risk (Chen & 
Goodson, 2007).   
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Additional factors that play a role in the decision to undergo carrier testing are knowledge 
about the condition, socioeconomic background and ethnic group.  People with more 
knowledge, higher socioeconomic status or White are more likely to be tested (Chen & 
Goodson, 2007).  Factors that play a role in individuals‟ decision to decline carrier testing, 
are the reluctance to terminate a pregnancy and a perceived low risk of being a carrier 
(Decruyenaere et al., 1998).  Individuals that considered their options and ultimately 
decided to have carrier testing, have a low tolerance for ambiguous test results and the cost 
of the test (Chen & Goodson, 2007).    
 
Although the decision to have carrier testing is dependent on a number of factors, the 
decision is a highly subjective one and will differ between individuals.  Some will see it as 
a benefit whereas others may see it as unnecessary.  A questionnaire based study on at-risk 
carriers for haemophilia, an X-linked bleeding disorder, showed that only 49% of the 
individuals had carrier testing although more than 95% of the individuals in the study 
thought that carrier testing is useful (Varekamp et al., 1990).  A reason for the lower 
percentage of individuals that had testing compared to those who thought it helpful, is 
because the more distant at-risk individuals in a family (cousins and nieces) were less 
informed about the availability of carrier testing (Varekamp et al., 1990).   
 
1.4.1.1 In DMD/BMD families 
In a study by Eggers, Pavanello, Passos-Bueno and Zatz (1999) where information was 
obtained retrospectively from files and telephonic interviews with patients, the decisions of 
263 at-risk individuals were recorded after they received genetic counselling. In the study 
it was shown that more DNA tests were requested by individuals from higher socio-
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educational levels and/or if they had one or more individuals in the family that had died as 
a result of DMD (Eggers et al., 1999).  The experience of having lost an affected DMD 
individual greatly influenced the behaviour of at-risk individuals regarding genetic testing 
(Eggers et al., 1999).  They also showed that an individual‟s decision to proceed with 
testing depends on beliefs about termination of pregnancy (Eggers et al., 1999).  A major 
reason for carrier testing in DMD/BMD is to assist in the reproductive decisions of at-risk 
individuals.   
 
1.4.2 Reproductive decisions of at-risk individuals 
At-risk individuals and their partners facing reproductive decisions often experience high 
levels of anxiety and need to consider a number of options that would be acceptable and 
available to them.  These reproductive decisions include the choice to have children, the 
timing of when to start a family, or once pregnant, the decision to continue with prenatal 
diagnosis and possible termination of a pregnancy, or choosing the non-biological route of 
adoption or oocyte donation.   The anxiety couples experience when making decisions is 
exacerbated by the risk to have an affected child, anticipation of a painful prenatal 
diagnostic procedure and the associated miscarriage risk, the difficulty to know what to do 
if the at-risk individual is pregnant with an affected child, and lastly the knowledge that 
choosing any one of the options will have psychological consequences (Kadir et al., 2000).   
 
Decisions about reproductive choices are usually dynamic (Sawyer et al., 2006) and 
change either with new information that becomes available or with the coping strategies of 
the at-risk individuals and their partners.  A few factors may influence at-risk individuals‟ 
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decisions and include amongst others, religion, family pressure and previous experience 
with an affected individual (Kadir et al., 2000).   
 
Studies on families with haemophilia, showed that individuals with a family history of the 
condition, chose to have children at a later stage in their life (Tedgård, Ljung & McNeil, 
1999).  A large proportion of at-risk haemophilia carriers and CF carriers chose not to have 
any children/have more children mainly because they did not want to pass the defective 
gene on to their children but also because of a previous experience with the condition and 
not wanting to terminate an affected child (Henneman et al., 2001; Kadir et al., 2000).   
Interestingly, the mean number of children born to at-risk haemophilia carriers did not 
differ from the number of children born to individuals not at risk of carrying the mutation 
(Tedgård et al., 1999).  However, this study and others showed that the majority of at-risk 
individuals that had an affected child chose not to have further pregnancies (Kelly, 2009; 
Tedgård et al., 1999).  It has been shown that approximately 75% of individuals with 
affected children who chose to have more children elected not to have prenatal diagnosis 
(Kelly, 2009).  
 
In families with haemophilia, the decision of at-risk individuals to continue with prenatal 
diagnosis depends strongly on their beliefs about termination of pregnancy after a positive 
result and also on the presence of a family history.  Individuals in favour of termination of 
an affected pregnancy are more likely to opt for prenatal diagnostic testing (Tedgård et al., 
1999).  Women that do not approve of termination tend to decide against prenatal 
diagnosis.  These women are also more likely not to have further children after the birth of 
an affected child (Tedgård et al., 1999).  It is important that individuals realise that prenatal 
diagnosis does not necessarily have to be followed by termination of the pregnancy, it can 
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simply function as preparation for the couple for the outcome or necessary medical 
intervention after the birth of an affected child.   
 
Most studies on reproductive behaviour are retrospective, and the decisions made by 
individuals in a counselling session or immediately after receiving information about 
carrier status are not definitive.  A study that looked at the decisions individuals made 
about future reproduction compared with their actual behaviour, found that more than half 
of the individuals who planned not to have further children continued to have more 
children.  These behaviours were strongly linked with the individual‟s experience with an 
affected child or their sense of disease burden.  The authors also found that once an 
affected child was born, parents also changed their minds regarding prenatal diagnosis and 
termination of pregnancy (Sawyer et al., 2006). 
 
1.4.2.1 In DMD/BMD families 
Eggers et al. (1999) categorised the genetic risk of having a DMD affected son as very low 
(0-4%), low (5-9%), intermediate (10-24%) and high (>25%). They found that women 
with a high risk did not differ in their reproductive and testing decisions from those women 
with lower genetic risks (≤24%) (Eggers et al., 1999).   In their study on at-risk individuals, 
they also found that sisters of affected DMD individuals did not reproduce less and did not 
request DNA tests more frequently than their at-risk cousins, aunts and nieces. They also 
showed that 75% of the sisters had an intermediate to high genetic risk (Eggers et al., 
1999). 
 
20 
 
However, Hutton and Thompson (1976) showed, with their questionnaire based study that 
included 122 at-risk females, that the risk of being a carrier discouraged ~81% of women 
from having children. They also showed that the number of women who chose to have 
children increased with a decrease in their risk to have affected children (Hutton & 
Thompson, 1976).  A record based study on potential DMD carriers in Wales from 1971-
1986 showed that many women at high risk of being carriers chose not to have children or 
deliberately delayed having children (Norman, Rogers, Sibert & Harper, 1989).  A 
prospective study on 574 at-risk individuals showed that mothers of affected boys more 
often chose not to have further children (Zatz, 1983). 
 
1.4.3 Uptake of Genetic Counselling  
Mothers of boys affected with haemophilia, rated the genetic counselling services as either 
„extremely‟ or „very‟ useful (Sawyer et al., 2006).  In light of this, it is expected that the 
uptake of genetic counselling services should be high. However, very few studies mention 
the decisions of at-risk individuals to undertake genetic counselling.    
 
A study on the uptake of genetic counselling by individuals in families with breast/ovarian 
cancer, showed that individuals were less likely to have genetic counselling when the 
proband had cancer (Hagoel et al., 2000).  Individuals were also less likely to have genetic 
counselling if they were referred by a doctor (and not self-referred) and if they were from 
the older generation in a family.  Younger individuals and first-degree relatives were more 
likely to accept genetic counselling (Hagoel et al., 2000).   
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In families with colorectal cancer, younger, more highly educated individuals and 
individuals with more affected people in the family, were more likely to have genetic 
counselling (Glanz, Grove, Lerman, Gotay & Le Marchand, 1999).  Other factors that 
positively influence the decision to undertake genetic counselling include increased anxiety 
and perception of risk, the availability of family social support, and the individual‟s need to 
obtain more information on the potential benefits and risk of genetic testing (Glanz et al., 
1999).  Factors that can negatively influence decisions to undertake genetic counselling 
include the cost of the service, the fear of the emotional impact on the family, the belief 
that the service is not beneficial, the distance from the genetic counselling clinic and the 
time commitments for the first and follow-up sessions (Geer, Ropka, Cohn, Jones & 
Miesfeldt, 2001).  
 
1.4.3.1 In DMD/BMD families 
The researcher found limited literature on DMD/BMD individuals and genetic counselling.  
A study on individuals that received genetic counselling showed that after a couple of 
years, mothers of affected boys could accurately recall their risks.  It also showed that the 
risks were not relayed to the younger generation, especially in families with isolated cases 
of DMD (Zatz, 1983).   
 
1.5 Motivation for research 
It is well documented that having genetic testing and being a carrier of a genetic disease 
has a psychosocial impact on the lives of individuals (Williams & Schutte, 1997). Very 
few articles on the psychosocial aspects of DMD/BMD have been published, the most 
recent being in 1999 (Eggers et al., 1999) and none in South Africa.  The researcher 
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proposed that the risk of being a DMD/BMD carrier, as in other conditions, may influence 
an individual‟s decisions regarding genetic counselling, carrier testing and reproduction.   
 
The literature available on the influence of potential carrier risk on reproduction and carrier 
testing is controversial.  The researcher felt that a retrospective study on a South African 
DMD/BMD population examining whether genetic counselling, carrier testing and 
reproductive decisions differ between at-risk individuals with varying risks would be 
valuable.  This study is the first in South African to investigate the behaviour of individuals 
at risk of being DMD/BMD carriers.  The findings of this study can assist in the 
improvement of genetic counselling services to a diverse population.  
 
1.6 Aims 
The aim of this study was to assess which members of DMD/BMD families came for 
genetic counselling and of those, who returned for subsequent counselling.  The study also 
aimed to identify individuals in these families at risk of being carriers of DMD/BMD, to 
assign their individual risks and group them into different risk categories. Lastly, the study 
aimed to investigate the influence of risk on the carrier testing, genetic counselling and 
reproductive decisions of individuals in the different risk groups.  
 
1.7 Study Objectives 
Part I: 1. To investigate the reasons individuals pursued genetic counselling. 
2. To establish whether at-risk individuals attend follow up genetic counselling 
sessions and the reasons for attending. 
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3. To establish whether the mutation of the affected individual in the family is 
known. 
Part II: 1. To determine the number of at-risk individuals from the family pedigree, 
assign carrier risks and categorise individuals according to their risk. 
2. To investigate the uptake of genetic counselling in the different risk 
categories. 
3. To examine the uptake of testing in the different risk categories. 
4. To compare the reproductive behaviour of the individuals in the different risk 
categories. 
 
In the next chapter the methodology of the study will be discussed.  This includes the data 
collection method, a description of the analysis used to test the significance of the data and 
also a description of the method used to determine the influence of different factors on the 
decisions of at-risk individuals.   
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2.0 METHODS 
 
The design of the study is quantitative, descriptive and correlational. It is a retrospective 
study and data was obtained by reviewing the genetic counselling files in the Division of 
Human Genetics, NHLS/WITS.  The study was unconditionally approved by the Human 
Research Ethics Committee at the University of the Witwatersrand, Johannesburg 
(Protocol number M080922, Appendix A). 
 
2.1 Study Sample 
The services offered by the Division of Human Genetics, NHLS/WITS, include genetic 
counselling, diagnostic and carrier testing.  The sample size consisted of 79 DMD/BMD 
patient files of individuals that attended the genetic counselling clinics regarding 
DMD/BMD from 01/01/1995 to 31/12/2008. The study sample included the maternal 
female relatives of DMD/BMD affected individuals.  They were identified from the 
genetic counselling files and are referred to as the „at-risk‟ individuals.  
 
2.2 File Collection 
At the genetic counselling session a file is created for every individual consulted.  The 
completed files contain demographic information, family history including family 
pedigree, medical history, information on the diagnosis, discussion points of the session 
and future management plans.  The files and listed records are kept at the Division of 
Human Genetics, NHLS/WITS.  The records were used by the researcher to identify all the 
DMD/BMD families seen between 1995 and 2008.   
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2.3 Data Collection 
2.3.1 Identification of at-risk individuals 
The at-risk individuals were women from DMD/BMD families that attended the genetic 
counselling clinic as well as maternal female relatives that had a risk of being a 
DMD/BMD carrier and who were identified from the family pedigrees.  The family 
pedigrees were obtained from the genetic counselling files.  The at-risk individuals were 
excluded or included based on the following criteria: 
 
Inclusion criteria: 
 Female relatives from the maternal side of affected individuals were included; the 
mothers, sisters, aunts, cousins, nieces and daughters (BMD families).  Included 
too, were maternal grandmothers and more distant relatives categorized as „other‟.   
 Only females of reproductive ages, 15 to 49 years, were included in the study.   
 
Exclusion criteria: 
 In situations where it was unclear what the ages of at-risk individuals were and the 
ages did not fall comfortably in the 15-49 year age group, individuals of that 
generation were excluded.   
 If an at-risk individual was 45 years of age, her older siblings or cousins were 
excluded from the study.   
 Similarly, if an at-risk individual was 18 years old, her younger siblings and 
cousins were excluded from the study.   
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2.3.2 Risk allocation 
2.3.2.1 In families with a history of DMD/BMD 
The following scenarios describe women that can be at-risk of being carriers of the disease 
causing mutation (van Essen et al., 1997): 
 A woman who has an affected son as well as another affected individual in the 
maternal family will be an obligate carrier of the disease causing mutation.   
 A woman with one or more affected brothers but no other family history of the 
condition is at-risk because her mother is at risk of being a carrier of the 
DMD/BMD mutation or can have either somatic or germline mosaicism. 
 A woman with affected family members and healthy children is still at-risk of 
being a carrier.  
 
It is relatively easy to estimate the carrier risks of female relatives from the family 
pedigree.  However, it is necessary to calculate their conditional risks on new information 
that becomes available by using Bayes‟ theorem.  Figure 2.1 can be used to illustrate the 
risk calculations of at-risk individuals.  In Figure 2.1, if I1 is an obligate carrier, her 
offspring (II1-5) are at 50% risk to inherit the disease causing mutation.  Daughters that 
inherit the mutation will be carriers (II2) of DMD/BMD whereas sons that inherit the 
mutation will be affected (II4).  The other siblings that did not inherit the mutation are not 
carriers, they are not affected and there is no risk to their children.   
 
 
 
27 
 
 
 
 
 
 
 
 
In Figure 2.1, both II3 and II5 are at 50% risk of being carriers.  Their carrier risks can 
only be clarified with molecular genetic testing or by linkage analysis.  In the absence of 
results, their assigned risk to be carriers would remain 50%.  The children would therefore 
have half their mother‟s risk of inheriting the mutation because they only receive one of 
the two X-chromosomes.  Thus II5‟s daughter (III6) has a 25% chance of inheriting the 
mutation and being a carrier and II5‟s sons would have a 25% chance of being affected 
with DMD/BMD.   
 
Unlike DMD affected individuals, BMD affected individuals (Figure 2.1, II4) can 
reproduce.  BMD affected individuals will always pass on the disease causing mutation to 
their daughters and they would thus be obligate carriers.  The sons of BMD individuals 
will not be affected because they inherit the Y-chromosome from their affected father.  
 
Figure 2.1: Pedigree of a family with a history of DMD/BMD. 
*Affected individuals will only reproduce in the case of BMD. 
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2.3.2.2 In families with an isolated occurrence of DMD/BMD 
In a de novo or „isolated‟ case where a woman has one affected son and no family history 
of the condition, the following scenarios describe women that can be at-risk of carrying the 
disease causing mutation (van Essen et al., 1997): 
 A woman with an affected son can be a carrier if the mutation occurred in either her 
mother or father‟s germline 
 A woman with an affected son can have somatic mosaicism if the mutation 
occurred  after she was conceived 
 A woman with an affected son could have a germline mutation 
 A woman with an affected son could not be a carrier if the new mutation arose in 
her ovum resulting in a somatic mutation in her son 
 A woman with an affected son could also not be a carrier if the new mutation 
occurred after her son was conceived 
 A woman with more than one affected son and no family history of the condition 
can be a carrier, have somatic mosaicism or germline mosaicism. 
 Sisters of an affected male are at-risk of being carriers because their mother can be 
either a full carrier or have somatic or germline mosaicism 
 
In apparent de novo cases with one affected male, it is essential to clarify the carrier status 
of the mother so that her daughters and female relatives can be informed of their possible 
risk of being carriers. This would be important for young mothers with DMD/BMD 
children who are planning subsequent pregnancies.  
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To calculate the risks of the female relatives of an isolated DMD/BMD case it is assumed 
that males and females have equal mutation rates in their germ cells (Harper, 1998).  With 
de novo mutations, the risk of the mother being a carrier is 
2
/3 (66.6%) and the risk that the 
mutation was transmitted from the grandmother is 
1
/3 (33.33%) (Harper, 1998). 
 
 
 
 
Using Figure 2.2 as illustration, the carrier risk of the mother (II2) of the affected 
individual will be 
2
/3 and that of the grandmother (I1) will be 
1
/3.  The daughters of II2 will 
have half the risk of their mother which is 
1
/3.  The sisters of II2 will have half the risk of 
the grandmother (I1) which will be 
1
/6.   The daughter of II5 will have a 
1
/12 risk of being a 
carrier of the DMD mutation (Harper, 1998).  
 
Mothers of affected individuals that do not have a somatic mutation have an 8.6% 
recurrence risk based on likely germline mosaicism (Helderman-van den Enden et al., 
2009).  This means that brothers who inherit the same X-chromosome as their affected sib 
will have an 8.6% chance of being affected, and sisters that inherit the same X-
chromosome, have an 8.6% chance of carrying the disease causing mutation.   
Figure 2.2: Pedigree of a family with no history of DMD/BMD. 
*Affected individuals will only reproduce in the case of BMD. 
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The initial carrier risk assigned to an individual based on the family pedigree was adapted 
if testing information was available.  The risks were also recalculated with the use of 
Bayes‟ theorem if an individual at-risk of being a carrier had unaffected sons.  Finally, the 
carrier risks were halved to obtain an individual‟s reproductive risk, i.e. the risk to have an 
affected son.    
 
2.3.3 Recording information 
The women who attended the genetic counselling clinic and other at-risk individuals 
identified from the pedigrees were assigned individual numbers thus ensuring anonymity 
and confidentiality.  For each at-risk individual (women who attended the genetic 
counselling clinic and other identified at-risk women) the relevant information was 
collected from the genetic counselling file onto a data collection sheet (Appendix B).  
 
The data collection sheet consisted of six categories; Demographics, Family history of 
DMD/BMD, Genetic counselling, Risks, Carrier testing and Reproduction.  The 
demographics category included the ages and ethnicity of at-risk individuals.  The Family 
history of DMD/BMD section depicted information on the relationship of the at-risk 
individual to the affected individual and also the clinical diagnosis and molecular 
confirmation of the diagnosis in the family.  The section on Genetic counselling gathered 
information on the number of sessions or follow-up sessions attended by an individual and 
also the reasons for attendance as well as the referral sources.   
 
The Risks section indicated information on the number of at-risk individuals in a family, 
whether the family mutation was de novo, and included pedigree information and risk 
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calculations.  In this section, carrier risks were allocated to individuals and their 
reproductive risks were assigned. In the Carrier testing category it was shown if 
individuals had carrier testing and if they received results after testing.  Results obtained 
meant that individuals‟ risks were refined with either molecular or by linked marker 
analysis. 
 
In the Reproduction section, individuals were categorized into three groups based on their 
reproductive risks.  The three groups were defined as; Low risk with a 0-9% reproductive 
risk, Intermediate risk with a 10-24% reproductive risk, and High risk with a ≥25% 
reproductive risk.  From the genetic counselling files, the researcher recorded the decisions 
of at-risk individuals in terms of the number of children they had, whether they knew that 
they were at-risk, and if they knew, whether they chose to have more children.  When 
individuals chose to have further children, the decisions regarding prenatal testing and 
termination of pregnancy were recorded as well as the pregnancy outcome.      
 
The data collected were entered from the data collection sheets into an Excel sheet that 
contained all the required study variables.  
 
2.4 Data Analysis  
A statistician from the Department of Public Health was consulted to validate the analysis 
method of the data.  The two programs used with the analysis of data and presentation of 
results were STATISTICA Version 8.0 (StatSoft, 2008) and Excel.  STATISTICA was 
used for descriptive statistics that included averages, counts, means, and standard 
deviations (SD).  Contingency tables and the Pearson‟s Chi-square (χ2) were used to 
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determine the significance of the relationships between variables. The Pearson‟s chi-square 
can be used for „goodness-of-fit‟ or „independence‟ tests.  The „goodness-of-fit‟ test 
determines the association between the observed and expected frequency distributions.  
The „independence‟ test determines whether two paired variables independently affect an 
outcome, and is analysed with contingency tables (WikiDoc website, 2009).  
 
The uni- and multivariate logistic regression functions in STATISTICA were used to 
determine if independent variables (e.g. risk) influenced decisions of individuals (e.g. 
uptake of testing).   Logistic regression analysis is applied in studies where the outcome or 
dependent variable is measured in a categorical scale.  The analysis also uses likelihood 
estimation, i.e. it tests the „goodness-of-fit‟, proposes the probability for various outcomes 
and calculates the odds of one outcome occurring over another (Burns & Grove, 2001).  
The Excel program was used to generate pie charts, histograms and tables for the graphic 
illustrations of results obtained.  
 
Most of the data in the Demographics, Family history of DMD/BMD and Risk categories 
were presented as counts and/or percentages.  The ages and number of at-risk individuals 
per family was represented as the mean values with standard deviations.  The referring 
individuals documented in the Genetic counselling section were presented with counts and 
histograms.  The reasons why individuals attended genetic counselling and follow-up 
consultations were also represented with counts and histograms.  
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2.4.1 Analysis to determine the influences on individuals’ behaviour 
The behaviour of at-risk individuals in terms of genetic counselling was documented as a 
dichotomous outcome; they either attended genetic counselling or did not.  The same was 
documented for behaviour around carrier testing.  For reproductive decisions an 
individual‟s behaviour was measured as having children or not having children.  Decisions 
regarding the above can be influenced by a variety of factors.  The different variables that 
were thought to affect decisions regarding genetic counselling, carrier testing and 
reproduction are presented Table 2.1.  
 
Table 2.1: Variables analysed to determine their contribution on behaviour of individuals. 
 
Genetic Counselling 
(GC) 
Carrier Testing Reproduction 
Dichotomous outcome 
variable: 
1. GC – Yes/No 
2. GC follow-up – 
Yes/No 
Testing – Yes/No Children – Yes/No 
Independent categorical 
variables: 
Risk 
Relationship 
Ethnicity 
De novo mutation 
Age 
Risk 
Relationship 
Ethnicity 
De novo mutation 
Mutation known 
Affected children 
Age 
Risk 
Relationship 
Ethnicity 
De novo mutation 
Mutation known 
Age 
  
 
The variable risk consists of the three risk groups, Low (0-9%), Intermediate (10-24%) and 
High (≥25%) based on individuals reproductive risks.  The variable relationship contains 
five groups; mothers, sisters, aunts, cousins and distant.  The relationship data were 
initially captured in seven categories; mothers, sisters, aunts, cousins, daughters, nieces and 
other.  The „daughters‟ category was excluded from the statistical analysis of the study 
because of category size consisting of only one individual.  The newly formed „distant‟ 
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category is a combination of the „nieces‟ and „other‟ in order to increase the group 
numbers and to include the individuals in the analysis.  The ethnicity variable consisted of 
three groups; Black, White and Indian.  The de novo variable is a binary variable that 
documented a mutation in the family as de novo or not.   „Mutation known‟ and „affected 
children‟ are also binary variables with yes/no answers.  
 
2.4.2 Logistic regression  
The first step in determining the influence of these variables on decisions of individuals 
was to do a univariate logistic regression analysis on each variable and determining the 
relationship it had with the outcome.  The variables that showed a significant relationship 
to the outcome variable were then used to create a multivariate logistic regression model.  
The purpose of this model was to present contributions of the independent variables on the 
outcome simultaneously and to provide odds ratios for each variable to present the 
strengths of associations (Ostir & Uchida, 2000).  
 
In the next chapter the findings of the study will be reported. This includes demographic 
information on at-risk individuals, information on who attended genetic counselling, the 
reasons for attendance and the referral sources.  Results on the different mutations in the 
families will be reported.  The extensive findings on factors influencing the decisions of at-
risk individuals will be reported.   
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3.0 RESULTS 
 
The first aim of this retrospective study was to identify the at-risk individuals in all the 
families that attended genetic counselling for DMD/BMD at the Division of Human 
Genetics, NHLS/WITS, and to assign a carrier risk (based on the pedigree) and a 
reproductive risk (risk to have an affected son).  The next aim was to determine why at-risk 
individuals attended genetic counselling and follow-ups and also to establish who referred 
them for genetic counselling.  Finally, the researcher investigated the influence of 
reproductive risk on the behaviour of the at-risk individuals in terms of genetic 
counselling, carrier testing and reproduction, as well as the possible contributions of other 
factors.  
 
3.1 Study Sample  
Initially, 100 DMD/BMD files were identified from the records, kept in the Division of 
Human Genetics, NHLS/WITS.  Of the 100 files, 21 were excluded for various reasons: 9 
files could not be found, 7 files were found but lacked a considerable amount of 
information e.g. family history, and with 5 files the diagnosis was a neither DMD or BMD 
but another type of muscular dystrophy.  The study thus included 79 files; 62 DMD and 17 
BMD genetic counselling files.  From the 79 files, 237 at-risk individuals were identified 
that met the inclusion criteria. The file selection method is depicted in Figure 3.1. 
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100 DMD/BMD files 
21 files excluded: 
 9 files, not found 
 7 files, no 
information 
available 
 5 files, diagnosis not 
DMD/BMD 
 
79 DMD/BMD files 
included in data 
collection 
237 at-risk individuals 
included in data 
collection 
 
 
 
 
 
 
 
 
 
 
 
3.2 At-risk individuals 
The mean number of at-risk individuals per family was 3.5±3.3.  Of the 237 at-risk 
individuals, 127 (53,6%) individuals were White, 96 (40.5%) were Black, 14 (6%) 
individuals were Indian but none were from the Coloured population.  Ages were available 
for 116 at-risk individuals, their mean age was 29.4±8.4 years.   
 
3.2.1 Relationship to affected individual  
The majority of at-risk individuals were the aunts of affected individuals, and mothers and 
sisters made up a large proportion of the relationship distribution in families.  
Figure 3.2, illustrates the relationship distribution of the at-risk individuals in DMD/BMD 
families.  
Figure 3.1: Selection process of at-risk individuals 
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Figure 3.2: The relationship distribution of the at-risk individuals. 
 
3.2.2 Risk Allocations  
The 237 at-risk individuals were categorised into the three respective reproductive risk 
groups; Low, Intermediate and High (Table 3.1). 
 
Table 3.1: The number of at-risk individuals in each risk group and the average carrier 
and reproductive risks of the groups. 
 Number of at-risk 
individuals 
Average Carrier 
risk 
Average 
Reproductive risk 
Low risk group 112 10.6±5.8% 5.3±2.9% 
Intermediate risk group 39 31.1±4.0% 15.5±2.0%. 
High risk group 86 74±19.8% 37±9.9%. 
 
Table 3.2 summarises the relationship distribution of individuals in the three risk groups:  
The Low risk group mainly consisted of the cousins (85.29%) and aunts (69.51%).  The 
Intermediate risk group consisted of a high number of sisters (43.14%) and nieces 
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(42.86%).  The High risk group consisted mainly of the mothers of affected individuals 
(92.16%). 
 
Table 3.2: The relationships of the at-risk individuals in each risk group. 
 Low Intermediate High Total 
 N % N % N % N (100%) 
Mother 4 7.84 0 0.00 47 92.16 51 
Sister 15 29.41 22 43.14 14 27.45 51 
Aunt 57 69.51 8 9.76 17 20.73 82 
Cousin 29 85.29 3 8.82 2 5.88 34 
Niece 5 35.71 6 42.86 3 21.43 14 
Daughter 0 0.00 0 0.00 1 100.00 1 
Other 2 50.00 0 0.00 2 50.00 4 
Total 112 47.26 39 16.46 86 36.29 237 
 
3.2.3 Mutation in family 
Table 3.3 summarises the specific diagnosis in families, shows whether the diagnosis was 
confirmed with mutation analysis, and also indicates the type of mutation involved.  This is 
summarised in the three distinct risk groups.  Most individuals (76.8%, 182/237) had a 
diagnosis of DMD in their families, 47 of the 237 (19.8%) had a diagnosis of BMD in their 
families and the diagnosis was unconfirmed (could be either DMD or BMD) in the families 
of a few individuals (3.4%, 8/237).  With DMD/BMD the clinical symptoms of individuals 
can overlap and uncertainty of whether the condition is the milder DMD or more severe 
BMD arise; in these individuals the diagnosis would thus be unconfirmed.  
 
The prevalence of de novo mutations was high with the majority (71.3%, 169/237) of 
individuals being part of families with de novo mutations. Only 27% (64/237) of at-risk 
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individuals had the mutation in their family confirmed by molecular analysis.  Of these 
mutations 93.7% (60/64) were deletions and 6.3% (4/64) were duplications. 
   
Table 3.3: The diagnosis, presence and nature of DMD mutations in families of at-risk individuals. 
 Low Intermediate High Total 
 N % N % N % 
N 
(100%) 
Diagnosis in family 
DMD 84 46.15 30 16.48 68 37.36 182 
BMD 22 46.81 9 19.15 16 34.04 47 
Unconfirmed 
(DMD/BMD) 
6 75.00 0 0.00 2 25.00 8 
Total 112 47.26 39 16.46 86 36.29 237 
New or familial mutation 
Familial 18 26.47 11 16.18 39 57.35 68 
De Novo 94 55.62 28 16.57 47 27.81 169 
Total 112 47.26 39 16.46 86 36.29 237 
Mutation confirmed with molecular testing 
Mutation Confirmed 31 48.44 8 12.50 25 39.06 64 
Mutation not confirmed 81 46.82 31 17.92 61 35.26 173 
Total 112 47.26 39 16.46 86 36.29 237 
Type of mutation 
Deletion 30 50.00 6 10.00 24 40.00 60 
Duplication 1 25.00 2 50.00 1 25.00 4 
Unknown 81 46.82 31 17.92 61 35.26 173 
Total 112 47.26 39 16.46 86 36.29 237 
 
 
3.3 Genetic Counselling 
3.3.1 Referral source 
Of the 237 at-risk individuals identified in the genetic counselling files who met the 
inclusion criteria, 30.4% (72/237) attended Genetic Counselling (GC).  The individuals 
were mostly referred by medical professionals or were self referred.  Medical professionals 
that referred most patients were neurologists, who referred 25.0% (18/72) and 
paediatricians, who referred 19.4% (14/72) of the at-risk individuals that attended GC.  A 
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large proportion of individuals, 22.2% (16/72) were self-referred.  Figure 3.3 illustrates the 
referral sources and the number of individuals per risk group that were referred.   
 
 
Figure 3.3: A representation of the number of at-risk individuals in the different risk groups that 
attended genetic counselling and their referral sources. 
 
 
3.3.2 Reasons to attend Genetic Counselling and Genetic Counselling follow-
up sessions 
Of the 30.4% (72/237) at-risk individuals that attended GC, 22.2% (16/72) of the 
individuals belonged to the Low risk group, 11.1% (8/72) to the Intermediate risk group 
and 66.7% (48/72) to the High risk group.  Individuals attended GC for different reasons; 
50.0% (36/72) of individuals were referred for GC because they had an affected son, 2.8% 
(2/72) because of the concern that their son might be affected with DMD/BMD, 25.0% 
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(18/72) for reasons around family planning, and 15.3% (11/72) at-risk individuals attended 
GC because they were pregnant and wanted prenatal testing (Figure 3.4).   
 
 
Figure 3.4: The number of at-risk individuals per risk group that attended genetic counselling 
and their reasons for attending. 
 
Individuals in the High risk group attended GC mostly because they had an affected son, 
66.7% (32/48).  Individuals in the Intermediate and Low risk groups attended GC mainly 
for family planning; 62.5% (5/8) and 43.7% (7/16) respectively.  Individuals in the Low 
risk group were also more concerned with prenatal diagnosis, 31.3% (5/16). 
 
Only 31 (43.06%) at-risk individuals of the 72 that attended the first GC session attended a 
follow-up session.  As some individuals attended more than one follow-up session, the 
reasons for attending follow-up sessions were more than the number of individuals that 
attended follow-up GC.  Of the follow-up GC visits 46.3% (19/41) sought test results.  
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Other reasons for attending GC follow-up sessions were for family planning, prenatal and 
postnatal testing (Figure 3.5) 
 
 
Figure 3.5: The number of at-risk individuals in each risk group and their reasons for 
attending genetic counselling follow-up sessions. 
 
 
3.3.3 Factors influencing decisions to attend Genetic Counselling 
To establish what factors influenced individuals‟ decisions to either attend or not to attend 
GC, the chi-square and logistic regression analysis were performed on 236 of the 237 
(„daughter‟ category was excluded from the analysis as there was only one individual in 
this category) at-risk individuals identified in the GC files.  The variables identified that 
may influence an individual‟s decision to go for GC were mentioned in section 2.4.1, 
Table 2.1.  These variables were reproductive risk, relationship to proband, ethnicity, de 
novo mutation and age.  Using Chi-squared (χ2) analysis, it was shown that independently, 
risk (χ2=41.81, P<0.0001), relationship (χ2=112.09, P<0.0001), de novo mutations 
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(χ2=4.32, P<0.05) and age (χ2=11.78, P<0.005) significantly contributed to the decision of 
an individual to go for GC.  However, ethnicity did not significantly influence GC 
decisions (χ2=3.05, P>0.1). 
 
Using Chi-squared (χ2) analysis, the different factors; risk, relationship, de novo mutations, 
ethnicity and age, were shown not to be significantly associated with an individual‟s 
decision to attend the follow-up GC session (all P values are greater than 0.05).   
 
The odds ratios calculated for the different variables were deducted from the univariate 
logistic regression analysis, where each variable was tested independently for significance 
surrounding the decision to go for GC (Table 3.4).  In order to look at the combination of 
factors and what most significantly influences GC decisions, multiple logistic regression 
analysis was performed.  Two multiple regression models were constructed using the 
variables that significantly influenced decisions to go for GC (Table 3.4).  The first model 
included variables; risk, relationship and de novo mutations. The second model included 
the variables used in the first model as well as the ages of individuals.  Age was not 
considered in the first model because the ages for only 116 individuals were known; this 
reduced the sample size by more than half.  However, age plays a significant role in the 
decision to attend GC and was therefore included in model 2 for comparative reasons.  The 
results for both the univariate and multiple logistic regression analysis are discussed in the 
following sections: 
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Table 3.4:  Logistic regression analysis for the different variables with genetic counselling as the 
dependent variable.  
Factor 
Univariate Logistic 
Regression 
Multiple Logistic 
Regression (Model 1) 
 
Pearson χ2=247.57 
Multiple Logistic 
Regression (Model 2) 
 
Pearson χ2=165.01 
 
OR
¥
         
(95% CI*) 
P value 
OR         
(95% CI) 
P value 
OR         
(95% CI) 
P value 
Risk Group χ
2
=41.81     
High 
3.33 
(2.18 -  5.09) 
0.00 
1.37 
(0.65 - 2.92) 
0.40 
0.65 
(0.23 - 1.82) 
0.41 
Intermediate 
0.68 
(0.38 - 1.20) 
0.18 
0.68 
(0.32 - 1.42) 
0.31 
0.66 
(0.28 - 1.59) 
0.36 
Low Reference Reference Reference 
Relationship χ
2
=112.09   
Other 
0.24 
(0.05 – 1.26) 
0.09 
0.32 
(0.06 - 1.79) 
0.19 
0.75 
(0.08 – 6.85) 
0.80 
Cousin 
0.70 
(0.28 – 1.77) 
0.46 
0.72 
(0.26 - 1.99) 
0.53 
0.24 
(0.06 - 0.96) 
0.04 
Aunt 
0.10 
(0.03 – 0.35) 
0.00 
0.09 
(0.03 - 0.33) 
0.00 
0.08 
(0.02 - 0.39) 
0.00 
Sister 
2.64 
(1.29 – 5.35) 
0.01 
2.80 
(1.30 – 6.09) 
0.01 
2.29 
(0.72 – 7.20) 
0.16 
Mother Reference Reference Reference 
De Novo χ
2
=4.32   
Yes 
1.42 
(1.02 – 1.98) 
0.04 
1.24 
(0.75 - 2.07) 
0.39 
0.64 
(0.30 - 1.38) 
0.25 
No Reference Reference Reference 
Age (N=116) χ2=11.78 
Excluded 
 
Group 1      
(15 to 25 yrs) 
0.39 
(0.22 – 0.68) 
0.00 
0.59 
(0.26 - 1.36) 
0.22 
Group 2      
(26 to 35 yrs) 
1.53 
(0.89 – 2.63) 
0.12 
1.81 
(0.82 - 4.02) 
0.14 
Group 3      
(36 to 49 yrs) 
Reference Reference 
Total  N   236 115 
 
¥  
Odds Ratio 
* Confidence Interval 
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3.3.3.1 Reproductive risk 
Table 3.4, shows that individuals in the High risk group differed significantly in their 
decision to go for GC compared to the Low risk group individuals.  The odds ratio or 
likelihood for the High risk group to go for GC was 3.33 more than for the Low risk group 
(95% CI 2.18 – 5.09, P<0.0001).   
 
Correcting the association between risk and the decision to go for GC, by taking into 
account the influence of relationship, de novo mutation and age, the association was no 
longer significant (Table 3.4). 
 
3.3.3.2 Relationship to proband  
The following relationships were documented: mothers, sisters, aunts, cousins, nieces, 
daughters and other.  The category „other‟ included individuals that were more distantly 
related.  For the analysis to test for an association between relationship and GC, the 
category „daughters‟ was excluded, as this group contained only one individual.  The more 
distantly related individuals in categories „nieces‟ and „other‟ were grouped together in 
order to increase the number of individuals in the group for analysis, and the new group 
was referred to as „distant‟.   Figure 3.6 depicts the 236 at-risk relatives of affected 
individuals that attended GC and follow-up GC. 
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Figure 3.6: The relationship distribution of family members of DMD/BMD affected 
individuals, who attended genetic counselling and follow-up genetic counselling.  
 
 
More mothers of affected individuals attended GC (Figure 3.6).  The aunts of affected 
individuals were 0.10 times as likely to go for GC as the mothers (95% CI 0.03 – 0.35, 
P<0.001).  However, the sisters of affected individuals were 2.64 times more likely to 
attend GC than the mothers of these individuals (95% CI 1.29 – 5.35, P<0.05).   The 
analysis also showed that cousins and more distantly related individuals were less likely to 
attend GC compared to the mothers (Table 3.4).  
 
Multiple logistic regression showed that the relationship to the affected individual plays a 
significant role in decisions surrounding GC.  In Model 1, the odds ratios for aunts and 
sisters did not change even after the contribution of relationship was corrected for the 
variables; risk and de novo mutation.  The relationships continued to play a significant role 
in the GC decision.  However, in Model 2, after the odds ratios were adjusted for risk, 
51 51
82
34
18
43
19
2
5
1
21
8
0 1 0
0
10
20
30
40
50
60
70
80
90
Mother Sister Aunt Cousin Distant
N
u
m
b
er
 o
f 
a
t-
ri
sk
 in
d
iv
id
u
a
ls
Relationship to affected individual
Number of individuals in each group
Attended GC
Attended GC Follow-up
47 
 
relationship, de novo mutation and age, being a „sister‟ did not have a significant influence 
on the GC decision.  The „aunt‟ relationship was still highly significant and the 'cousin‟ 
relationship seemed to be significant when age was taken into consideration.   
 
3.3.3.3 De novo mutations 
Another significant association is the relationship between de novo mutations in a family 
and the likelihood that individuals in those families will attend GC.  The results in Table 
3.4 show that individuals in de novo families were 1.42 times more likely to attend GC 
than their counterparts (95% CI 1.02 – 1.98, P<0.05).  The contribution of de novo 
mutations proved not to be significant when the other factors (risk and relationship) were 
taken into account. 
 
3.3.3.4 Age 
The age of individuals also played a significant role in making decisions about GC.  The 
decision of Group 1 (15 to 25 years) individuals differed significantly from those of Group 
3 (36 to 49 years) in that they were 2.56 times more likely (95% CI 1.47 – 4.55, P<0.001) 
not to attend GC than the older individuals (or 0.39 times as likely to attend GC).  The 
contribution of age proved not to be significant when the other factors (risk, relationship 
and de novo mutation) were taken into account. 
 
3.4 Carrier Testing 
The decision of individuals to have carrier testing was analysed for 236 of the 237 
(„daughter‟ category was excluded from the logistic regression analysis as there was only 
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one individual in this category) at-risk individuals identified from the GC files.  The ages 
of 116 individuals were known.  The group that did not have testing consisted of 54 
individuals with a mean age of 27.3±9.03.  The group electing to have carrier testing, 
consisted of 62 individuals, with a mean age of 31.1±7.4.   The High risk group had the 
largest percentage of individuals that chose to have carrier testing 59.3% (51/81), the Low 
risk group had 20.5% (23/112) who had testing, and the Intermediate risk group had the 
lowest percentage with 5% (2/39) of the individuals in the group having had carrier testing.  
Figure 3.7 graphically represents the individuals in the different risk groups that had carrier 
testing and the number of individuals that obtained results. 
 
 
Figure 3.7: Carrier testing and results for individuals in the different risk groups. 
 
3.4.1 Factors influencing decisions to take up carrier testing 
The variables identified that could influence an individual‟s decision to take up carrier 
testing were mentioned in section 2.4.1, Table 2.1.  These variables were reproductive risk, 
relationship to proband, ethnicity, de novo mutation, mutation known, affected children 
and age.   
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The variables that independently had a significant influence on individuals‟ decision to 
undertake carrier testing were risk (χ2=49.11, P<0.0001), relationship to the proband 
(χ2=68.08, P<0.0001), whether an individual had an affected child (χ2=38.48, P<0.0001) 
and age (χ2=10.89, P<0.005).  Variables that did not have a significant influence on 
decisions to undertake carrier testing were ethnicity (χ2=3.95, P>0.1), whether the mutation 
was known (χ2=1.97, P>0.1) or if the mutation was de novo (χ2=0.97, P>0.2).  Only the 
variables with significant P values were included in the multiple logistic regression models 
(Table 3.5). 
 
3.4.1.1 Reproductive Risk 
Using univariate logistic regression analysis it was shown that individuals in the High risk 
group were 5.34 times (95% CI 3.00 – 9.48, P<0.0001) more likely to undertake carrier 
testing than the Low risk group.  Analysis also showed that the Intermediate risk group was 
0.20 times (95% CI 0.07 – 0.52, P=0.001) as likely to undertake carrier testing when 
compared to the Low risk group.  
 
Using multiple logistic regression analysis it was shown that the reproductive risk of an 
individual significantly contributed to carrier testing decisions even after all the other 
variables were taken into account.   After correcting for relationship and age, individuals 
in the High risk group were 2.53 times (95% CI 1.01 – 6.32, P<0.05) more likely to have 
carrier testing than the Low risk group.  The Intermediate risk group were 0.09 times (95% 
CI 0.03 – 0.34, P<0.001) as likely to have carrier testing.  
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Table 3.5: Logistic regression analysis for the different variables with carrier 
testing as the dependent variable. 
Factor 
Univariate Logistic 
Regression 
Multiple Logistic 
Regression  
 
Pearson χ2=108.91 
 
OR
¥
         
(95% CI*) 
P value 
OR         
(95% CI) 
P value 
Risk Group χ
2
=49.11  
High 
5.34  
(3.00 - 9.48) 
0.00 
2.53 
(1.01 - 6.32) 
0.05 
Intermediate 
0.20  
(0.07 - 0.52) 
0.00 
0.09 
(0.03 - 0.34) 
0.00 
Low Reference Reference 
Relationship χ
2
=68.08  
Other 
0.35  
(0.10 - 1.16) 
0.09 
2.68 
(0.33 - 21.79) 
0.36 
Cousin 
0.72  
(0.34 - 1.54) 
0.40 
0.29 
(0.08 - 0.99) 
0.05 
Aunt 
0.26  
(0.13 - 0.53) 
0.00 
0.17 
(0.05 - 0.60) 
0.01 
Sister 
2.11  
(1.17 - 3.80) 
0.01 
3.49 
(1.03 - 11.83) 
0.04 
Mother Reference Reference 
Age (N=116) χ2=10.89  
Group 1      (15 to 
25 yrs) 
0.45 
(0.26 - 0.78) 
0.00 
0.53 
(0.23 - 1.25) 
0.15 
Group 2      (26 to 
35 yrs) 
2.00 
(1.18 - 3.36) 
0.01 
2.49 
(1.26 - 4.90) 
0.01 
Group 3      (36 to 
49 yrs) 
Reference Reference 
Affected Children 
(N=131) 
χ2=38.48 
Excluded Yes 
3.42 
(2.26 - 5.18) 
0.00 
No Reference 
Total  N   115* 
¥  
Odds Ratio 
* Confidence Interval 
 
 
3.4.1.2 Relationship to affected individual 
Univariate logistic regression showed that the relationship to an affected individual 
significantly contributed to the decision to undertake carrier testing.  The aunts of 
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DMD/BMD affected individuals were 0.26 times (95% CI 0.13 – 0.53, P<0.001) as likely 
to have carrier testing as the mothers of affected individuals.  In other words the aunts were 
3.84 times less likely to have carrier testing when compared to the mothers.  The sisters of 
affected individuals were 2.11 times (95% CI 1.17 – 3.80, P=0.01) more likely to have 
carrier testing than the mothers.    
 
After adjusting the odds ratios for risk and age with multiple logistic regression, 
relationship still had a significant influence on the decision to have carrier testing.  
Cousins and aunts were less likely to have carrier testing than mothers with odds ratios of 
0.29 (95% CI 0.08 – 0.99, P<0.05) and 0.17 (95% CI 0.05 – 0.60, P<0.01) respectively.  
Sisters were 3.49 times (95% CI 1.03 – 11.83, P<0.05) more likely to have carrier testing 
than mothers. 
 
3.4.1.3 Age 
Individuals in the youngest reproductive group (15 – 25 years), were 0.45 times (95% CI 
0.26 – 0.78, P<0.01) as likely to have carrier testing as individuals of older reproductive 
age (36 – 49 years).  The age group 26 – 35 years of age were 2 times (95% CI 1.18 – 3.80, 
P=0.01) more likely to have carrier testing than the oldest group.   
 
Adjusting the relationship between age and the decision to have carrier testing by taking 
into account the reproductive risk and relationship to the affected individual, it was found 
that age-group 2 (26 – 35 years) were 2.49 times (95% CI 1.26 – 4.90, P<0.01) more likely 
to have carrier testing than the older individuals (36 – 49 years).   
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3.4.1.4 Affected child 
Individuals with DMD/BMD affected children were 3.42 times (95% CI 2.26 – 5.18, 
P<0.0001) more likely to have carrier testing when compared to individuals that did not 
have affected children.  
 
The variable affected children, was not included in the multiple logistic regression model 
because of the limited overlap of information available on the ages of individuals and 
whether they had affected children.  With the inclusion of affected children in the model, 
the number of individuals in the data was reduced to N=56 and the model was no longer 
significant.  
 
3.5 Reproduction 
The analysis on reproduction was performed on a sample size of 218 at-risk individuals, 
identified from the GC files.  Information on whether individuals had children was 
available for only 218 individuals, ages were available for 114 of the 218.  Individuals with 
children (69/114) had a mean age of 32.8±7.5 and individuals without children (45/114) 
had a mean age of 23.8±6.7.  Of the individuals in the Low risk group 69.5% (66/95) had 
children, 38.5% (15/39) in the Intermediate risk group and 78.6% (66/84) in the High risk 
group (Figure 3.8).   
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Figure 3.8: The number of at-risk individuals in the different risk groups with 
and without children. 
 
Of the individuals in the different risk groups that had children, the following percentages 
of the group had children affected with DMD/BMD: The Low risk group consisted of 
7.1% (4/56) individuals that had affected children, the Intermediate risk group did not have 
affected children, and the High risk group had the largest percentage of individuals with 
affected children, 78.1% (50/64) (Figure 3.9). 
 
 
Figure 3.9: The number of at-risk individuals in the different risk categories with 
children and those with affected and unaffected children. 
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3.5.1 Factors influencing decisions to reproduce  
The variables identified that could have influenced an individual‟s decision to have 
children were mentioned in section 2.4.1, Table 2.1.  These variables were reproductive 
risk, relationship to proband, ethnicity, de novo mutation, mutation known and age.  
 
The variables that independently had a significant influence on an individual‟s decision to 
have children were risk (χ2=19.83, P<0.0001), relationship to the proband (χ2=37.32, 
P<0.0001), ethnicity (χ2=14.22, P<0.001), de novo mutation (χ2=5.16, P<0.05) and age 
(χ2=25.27, P<0.0001).  Whether the mutation in the family was known did not have a 
significant influence on the decision to have children (χ2=0.067, P>0.5). Only the variables 
with significant P values were included in the multiple logistic regression models (Table 
3.6). 
 
3.5.1.1 Reproductive Risk 
Univariate logistic regression showed that individuals in the High risk group were 2.11 
times (95% CI 1.37 - 3.26, P<0.0001) more likely to have children than the Low risk 
group.  Analysis also showed that the Intermediate risk group was 0.36 times (95% CI 0.22 
- 0.59, P<0.0001) as likely to have children when compared to the Low risk group.  
However, after adjusting the relationship between risk and children for the other variables 
(relationship, de novo mutation and ethnicity) no significant influence on the decision to 
have children was found. 
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Table 3.6: Logistic regression analysis for the different variables with having 
children as the dependent variable. 
Factor 
Univariate Logistic 
Regression 
Multiple Logistic 
Regression (Model 1) 
 
Pearson χ2=169.94 
 
OR
¥ 
         
(95% CI*) 
P value 
OR         
(95% CI) 
P value 
Risk Group χ
2
=19.83  
High 
2.11 
(1.37 - 3.26) 
0.00 
0.91 
(0.46 - 1.81) 
0.79 
Intermediate 
0.36 
(0.22 - 0.59) 
0.00 
0.67 
(0.36 - 1.24) 
0.20 
Low Reference Reference 
Relationship χ
2
=37.32  
Distant 
0.70 
(0.22 - 1.09) 
0.08 
0.67 
(0.27 - 1.70) 
0.40 
Cousin 
0.32 
(0.37 - 1.42) 
0.35 
0.58 
(0.28 - 1.21) 
0.14 
Aunt 
1.63 
(2.87 -9.13) 
0.00 
4.10 
(2.19 - 7.67) 
0.00 
Sister Reference Reference 
De novo  χ
2
=5.16  
Yes 
1.42 
(1.05 – 2.85) 0.02 
1.07 
(0.65 - 1.75) 0.80 
No Reference Reference 
Ethnicity χ
2
=14.22  
Black 
2.04 
(1.21 - 3.46) 
0.01 
1.86 
(0.98 - 3.53) 
0.06 
White 
0.60 
(0.37 - 0.96) 
0.03 
0.74 
(0.40 - 1.35) 
0.32 
Indian Reference Reference 
Age (N=116) χ2=25.27 
Excluded 
Group 1      
(15 to 25 yrs) 
0.22 
(0.12 - 0.42) 
0.00 
Group 2      
(26 to 35 yrs) 
1.07 
(0.58 - 1.98) 
0.83 
Group 3      
(36 to 49 yrs) 
Reference 
Total  N   166* 
¥  
Odds Ratio 
* Confidence Interval 
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3.5.1.2 Relationship to proband 
In this study, the majority of individuals had children (62%, 147/237).  The „aunts‟ of 
affected individuals was the group with the largest proportion 83.8% (62/74) of individuals 
that had children.  Of the cousins 42% (11/26), of the sisters 35.4% (17/48) and of the 
more distant relatives 33.3% (6/18) had children (Figure 3.10).  
 
 
Figure 3.10: Relatives of the affected individual with the number of individuals in each 
group that had children and did not have children. 
 
The relationship „mother‟ was not included in the analysis because the relationship was not 
predictive of whether an individual would have children or not, as all mothers had children 
(Figure 3.10).  The „daughter‟ category was also excluded from the logistic regression 
analysis as this category consisted of one individual.  
 
Univariate logistic regression showed that the relationship to an affected individual 
significantly contributed to the decision to have children.  The aunts of DMD/ BMD 
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affected individuals were 5 times (95% CI 2.87 – 9.13, P<0.0001) more likely to have 
children than the sisters of affected individuals.   
 
After adjusting the odds ratios for risk, ethnicity, and de novo mutation with multiple 
logistic regression, relationship still had a significant influence on the decision to have 
children.  Aunts were 4.1 times (95% CI 2.19 – 7.67, P<0.0001) more likely to have 
children than the sisters of affected individuals.   
 
3.5.1.3 Ethnicity 
Using univariate logistic regression it was shown that individuals from the Black ethnic 
group were 2 times (95% CI 1.21 - 3.46, P<0.01) more likely to have children than Indian 
individuals.  White individuals were 0.60 times (95% CI 0.37 - 0.96, P<0.05) as likely to 
have children as Indian individuals (or 1.7 times more likely not to have children).  
However, after adjusting the relationship between ethnicity and children for the other 
variables (Table 3.6), no significant influence on the decision to have children was noticed. 
 
3.5.1.4 De novo mutation 
Using univariate logistic regression it was shown that individuals from families with de 
novo mutations were 1.42 times (95% CI 1.05 – 2.85, P<0.05) more likely to have children 
than individuals with previous affected individuals in their families.  However, after 
adjusting the relationship between de novo mutation and children for the variables, risk, 
relationship and ethnicity, the de novo mutation did not have a significant influence on the 
decision to have children.  
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3.5.1.5 Age 
Individuals in the youngest reproductive group (15 – 25 years) were 0.22 times (95% CI 
0.12 - 0.42, P<0.0001) as likely to have children as individuals of older reproductive age 
(36 – 49 years).  In other words, Group 1 (15 – 25 years) individuals were 4.5 times more 
likely not to have children than individuals in Group 3 (36 – 49 years).    
 
Age was initially excluded from the multiple logistic regression model because of the 
limited information available and the fact that the sample size decreased if age was 
included.  Age was included in a second multiple logistic regression model, however the 
model did not show any significance and was therefore not included in the results.  
 
3.5.2 Knowledge about potential carrier risk  
Of the 237 individuals in the study, limited information was available on the knowledge 
individuals had about their risk. The information available showed that 46 individuals 
knew that they were at risk of carrying the disease causing gene, of whom 50% (23/46) 
chose to have children, 4.3% (2/46) chose not to have children, 6.5% (3/46) delayed having 
children, but for 39% (18/46), the decision to have children could not be obtained from the 
counselling files.  Figure 3.11 graphically represents the number of individuals in each risk 
group that knew about their potential risk and their decisions regarding reproduction, 
prenatal testing, termination of pregnancy and also the pregnancy outcome.  
 
In the High risk group, 22 of the 86 individuals (25.6%) were aware of their potential risk 
to be carriers. Of 22 individuals, 16 (72.7%) decided to have children and 13 of the 16 
(81.3%) had prenatal testing.  Limited information was available on decisions to terminate 
59 
 
a pregnancy and on the pregnancy outcomes.  Of the 16 High risk individuals that had 
children, information on termination of pregnancy was available on 10 individuals 
(45.5%);  four of the individuals would have terminated a pregnancy and 6 would not.  The 
pregnancy outcomes for the 16 individuals in the High risk group that knew about their 
potential risk and proceeded to have children was as follows; 4 affected boys were born 
(25%), 5 unaffected boys (31.3%), 1 daughter (6.3%), 1 pregnancy was terminated (6.3%) 
but the outcome for 5 pregnancies was unknown. 
 
In the Intermediate risk group, 7 of the 39 individuals (17.9%) were aware of their 
potential risk to be carriers. Of these individuals, 1 (14.3%) decided to have children and 
did not have prenatal testing.  Information on the decision to terminate a pregnancy and on 
the pregnancy outcome was unavailable.   
 
In the Low risk group, 17 of the 112 individuals (15.2%) were aware of their potential risk 
to be carriers. Of 17 individuals, 9 (52.9%) decided to have children and 5 (55.6%) had 
prenatal testing.  Information on whether individuals would terminate an affected 
pregnancy was not available. Limited information was available on the pregnancy 
outcomes, 2 individuals (22.2%) had unaffected boys, the other pregnancy outcomes were 
unknown. 
 
The results obtained in the different focus areas of the study and the limitations 
encountered during the process of the study will be discussed in detail in Chapter Four.  
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Figure 3.11: At-risk individuals in the different risk groups who were aware of their potential risks, their decisions to have children and prenatal testing, their 
decisions about termination of pregnancy and the outcomes of their pregnancies.  
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4.0 DISCUSSION 
 
The first aim of this study was to assess which members of DMD/BMD families came for 
genetic counselling and of those, who returned for subsequent counselling.  The study also 
aimed to identify individuals in these families at risk of being carriers for DMD/BMD, to 
assign their individual risks and group them into different risk categories. Lastly, the study 
aimed to investigate the influence of risk on the carrier testing, genetic counselling and 
reproductive decisions of individuals in the different risk groups.  After careful 
consideration, the researcher realised that risk was not the only influential factor when 
having to decide about testing, reproduction and genetic counselling and the study 
therefore included other contributing factors.   
 
4.1 At-risk individuals  
From the files included in the study, 237 at-risk individuals were identified.  The mean 
number of at-risk individuals per family was 3.5±3.3.  The at-risk individuals were mostly 
Black and White individuals with a minority of the individuals from Indian ethnicity and 
none from the Coloured population.  This result is therefore not representative of the South 
African population. 
 
The at-risk individuals identified from the pedigrees were predominantly closely related 
individuals, mainly the aunts, mothers and sisters. The cousins and more distantly related 
individuals made up the rest of the at-risk group of individuals (Figure 3.1, p36).  The 
researcher considered that perhaps more information was available on the closely related 
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individuals because, the genetic counsellor did not ask about the more distantly related 
individuals or the individuals who attended GC did not have the required information.   
 
The at-risk individuals were categorised into the three risk groups; the Low risk group 
consisted mainly of the cousins and aunts (Table 3.2, p38), the Intermediate risk group of 
sisters and also nieces, whereas the High risk group comprised of mainly the mothers of 
affected individuals.  This result is consistent with the X-linked recessive inheritance 
pattern where the more distantly related individuals have a lower risk of carrying the 
mutation and the closely related individuals, a higher risk.  In this study, the Low and High 
risk groups contained individuals for whom risks could be further refined.  Factors that 
were used in Bayes‟ theorem to refine the at-risk individuals‟ risks were the number of 
healthy sons they had, and also whether they had carrier testing done.  The Intermediate 
risk group consisted of individuals where less information was available in terms of 
children and carrier testing, and their risk calculations therefore, were more dependent on 
the pedigree; thus the Intermediate risk group consisted of both closely and distantly 
related individuals.  
 
4.2 Diagnosis and mutations in families of at-risk individuals 
4.2.1 Diagnosis 
Most individuals in the study had a diagnosis of DMD in their families (Table 3.3, p39).  
This was expected because the prevalence of DMD is much higher (1 in 3,500) than the 
BMD prevalence (1 in 18,000).  A few individuals did not have a specific diagnosis in their 
families; the familial condition was either severe BMD or milder DMD.     
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Interestingly, 71.3% of the at-risk individuals were part of families with a de novo 
mutation.  This figure was much higher than expected and one might consider why more 
de novo families were seen for genetic counselling - the researcher speculates that these 
individuals could have had less knowledge of the condition and the inheritance thereof, and 
were therefore more likely to seek information.   
 
4.2.2 Mutations 
Only 27% of at-risk individuals had a confirmed mutation in their family, of which a large 
proportion had a deletion and a smaller proportion a duplication (Table 3.3, p39).  The 
number of individuals with a confirmed mutation in their families was of concern. 
However, until 2008 in South Africa only the „hotspot‟ regions were screened for deletions 
and duplications.  Screening the „hotspot‟ regions with multiplex PCR detects almost all of 
the DMD/BMD causing deletions, which account for 65% of the DMD causing mutations 
and 85% of the BMD mutations.  The new MLPA method was only introduced in 2008 
and is used to screen all 79 exons for deletions and duplications.  The MLPA method has 
greater specificity and a better detection rate of the DMD/BMD causing deletions and 
duplications, thus more individuals will learn their family specific mutation.  The 
researcher considered that more individuals will have carrier testing if the family mutation 
is known.  
 
4.3 Who refer individuals for genetic counselling? 
Medical professionals who referred individuals for GC were mostly neurologists and 
paediatricians.  A large proportion of individuals were also self-referred and low numbers 
of individuals were referred by general practitioners (GPs) and gynaecologists (Figure 3.3, 
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p40).    This corresponds to another South African study on CF, where the author found 
individuals were mostly referred by paediatricians and much less by physicians and 
gynaecologists (Macaulay, 2008).  By implication, only the individuals with affected 
children or where a concern about a child was raised would have been seen for GC.  Also, 
only individuals who were aware of their potential risk would have been seen for GC.  This 
is concerning as the researcher feels that more individuals should be seen regarding family 
planning and less because of affected children, and feels that more individuals could be 
referred by GPs and gynaecologists. Seeing individuals before they have children would 
allow them the opportunity to gain knowledge of their risk and reproductive options, which 
could promote informed decisions.  
 
4.4 Why do individuals attend genetic counselling? 
Individuals attended GC mainly because they had a child affected with DMD/BMD or 
were worried that a child may be affected.  A large proportion of at-risk individuals 
attended GC for family planning reasons and some individuals pertaining to antenatal 
testing (Figure 3.4, p41).  Considering the referring individuals (section 4.3), it is not 
unexpected that most individuals were seen for GC because of an affected child.  
 
Individuals attended the GC follow-up sessions mainly to get results for either carrier 
testing or confirmation of the condition.  This result was expected as the genetic 
counsellors and clinical geneticists at the Division of Human Genetics, NHLS/WITS prefer 
to give results face-to-face. Individuals also attended the follow-up sessions for family 
planning, prenatal and postnatal testing (Figure 3.5, p42).   
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4.5 Factors influencing the decision to attend Genetic Counselling  
In this study the following independent factors were found to influence the decision to 
have GC significantly; the reproductive risk of at-risk individuals, the relationship to the 
affected individual, de novo mutation and age.  
 
The researcher found that individuals in the High risk group were more likely to attend GC 
than individuals in the Low risk group (Table 3.4, p44).   Considering that the High risk 
group consisted mostly of mothers of affected individuals and the Low risk group mainly 
of aunts and cousins the result was not unanticipated.  Using logistic regression, it was 
shown that both the aunts and cousins were less likely to attend GC than the mothers 
(Table 3.4, p44).  However, the sisters of affected individuals were more likely to attend 
GC than the mothers.  In Chapter 1, it was discussed that in families with cancer, the first-
degree relatives were more likely to accept genetic counselling (Hagoel et al., 2000).  This 
correlates with this study where the mothers and sisters of affected individuals were more 
likely to attend GC.  It is well known that first-hand experience of a condition, either being 
affected oneself or having an affected family member, provides an individual with 
information on the burden of the condition on both the affected individuals as well as the 
rest of the family.  This lived experience affects individuals‟ decisions in terms of 
reproduction, prenatal testing and termination of pregnancy (Weil, 2000).  The researcher 
postulates that growing up with an affected sibling and witnessing the everyday reality of 
the condition also motivated the decision of sisters to attend GC.   
 
Another factor that impacted on individuals‟ decisions to attend GC was age.  When, 
comparing the younger individuals (15 – 25 years) with the older individuals (36 – 49 
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years), it was shown that the younger individuals were much less likely to attend GC.  This 
finding did not correlate with the study of Hagoel, et al. (2000) that found the younger 
individuals more likely to accept GC.  However, Zatz (1983) showed that younger 
individuals in DMD/BMD families were rarely informed by other family members about 
their risk, which could explain why they did not seek GC.  This researcher feels that 
younger individuals may have been less informed about their risk as well as the availability 
of the service.  However, a large proportion of the current study sample consisted of 
mothers of affected individuals and the age group 36 – 49 years consisted of more mothers 
that were referred for GC compared to the youngest (15 – 25 years) age group (results not 
reported in study).   
 
Using, multiple logistic regression, the researcher found that if all the factors that 
significantly influenced the decision to attend GC were considered simultaneously, the 
single most important predicting factor of whether an individuals would attend GC was the 
relationship to the affected individual.  The first degree relatives would seek GC more and 
the aunts and cousins would be less likely to attend GC.  This result indicates that first-
degree relatives were possibly more aware of their risk, had more knowledge of the 
condition and were more informed about the availability of genetic counselling. This also 
indicates that the family communication around DMD/BMD was lacking. Similarly, 
Hagoel, et al. (2000) found that first degree relatives in families with breast/ovarian cancer 
were more likely to attend GC.   
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This study did not identify any factors that could predict the decision of an individual to 
attend the GC follow-up session.  It seems that the most important factor in attending the 
follow-up session was to obtain results.  
 
4.6 Factors influencing the decision to have carrier testing 
The following variables were investigated for their contribution to the behaviour of 
individuals with regards to carrier testing:  reproductive risk, relationship to proband, 
ethnicity, de novo mutation, mutation known, affected children and age.  It was shown that 
reproductive risk, relationship to the affected individual, having an affected child and age 
influenced the decision to have carrier testing significantly.  
 
Individuals in the High risk group were much more likely to be tested than individuals in 
the Low risk group. The result does not correspond with the study by Eggers, et al. (1999) 
which found that women with a high risk did not differ in their testing decisions from those 
women with lower genetic risks (≤24%).  The researcher also found that individuals in the 
Intermediate risk group were less likely to have carrier testing than the Low risk group.  A 
study by Chen and Goodson (2007) showed that people with more knowledge are more 
likely to be tested.  The researcher questioned whether or not individuals in the 
Intermediate risk group had been aware of their potential carrier risk, as their actions did 
not indicate this.  
 
Eggers, et al. (1999) demonstrated that the sisters of affected individuals did not request 
more DNA tests than their at-risk aunts, cousins and nieces.  In contrast, this study showed 
that the aunts of affected individuals were much less likely to have carrier testing than the 
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mothers, and the sisters were twice as likely to have carrier testing than the mothers.  This 
study also showed that the more distantly related individuals were less likely to have 
carrier testing (although this association was not significant using Chi-square analysis).  
This finding is in keeping with a study by Varekamp, et al. (1990) who found that more 
distantly related individuals are less informed about the availability of carrier testing and 
therefore have less testing.  
 
Individuals with DMD/BMD affected children were a great deal more likely to have carrier 
testing compared to individuals that did not have affected children.  This finding is 
comparable to a study that found at-risk individuals with unaffected children were less 
likely to have carrier testing (Chen & Goodson, 2007).  The authors of that study 
postulated that individuals with unaffected children perceived themselves being at a lower 
risk.  This researcher believes that mothers of affected children also had more testing 
because they were referred more to the GC clinics by their neurologists and paediatricians 
(section 4.3, p63). 
 
In this study the researcher found that individuals in the youngest reproductive group (15 – 
25 years) were less likely to have carrier testing than individuals of older reproductive age 
(36 – 49 years).  Also, the group, 26 – 35 years of age, were twice as likely to have carrier 
testing than the oldest group.  In section 3.3.3.4 (p47), it was found that younger 
individuals were less likely to attend GC and Zatz (1983) established that younger 
individuals were less informed about their risk than the older individuals.  This speculation 
can also explain why younger individuals were less likely to have carrier testing.  
However, in this study the oldest group of individuals were also less likely to have carrier 
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testing than the age group 26 – 35 years.  Although the reproductive ages used were 15 to 
49 years of age, the researcher feels that it can safely be assumed that the youngest (15 – 
25 years) and oldest (36 – 49 years) groups had fewer individuals that were actively 
planning a family and that the decision to start a family would influence decisions around 
carrier testing.  
 
Factors that were investigated for their contribution to the decision to have carrier testing 
and were shown not to be influential were ethnicity, whether the family mutation was 
known or if the mutation was de novo.  A study by Chen and Goodson (2007) showed that 
ethnicity influenced decisions surrounding carrier testing and that White individuals were 
more likely to be tested.  This does not correlate with the current study which showed that 
ethnicity did not significantly influence the decision to have carrier testing.   
 
4.7 Factors influencing the decision to have children 
The factors that significantly influenced the decision to have children were risk, 
relationship to the proband, ethnicity, de novo mutation and age.  The factor whether the 
family mutation was known, did not have a significant influence on the reproductive 
decision.  
 
One could infer that the risk of having an affected child would influence the decision to 
have children. Studies that examined the relationship between carrier risk and reproductive 
outcome differ in their findings.  In some studies, risk does not influence the decision to 
have children (Eggers et al., 1999; Tedgård et al., 1999).  The study by Tedgård, et al. 
(1999) on haemophilia carriers reported that the decision to have children did not differ 
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between at-risk haemophilia carriers and individuals who did not have a risk of being a 
carrier.  Similarly, Eggers, et al. (1999) reported that women with a high reproductive risk 
for DMD did not differ from individuals at low risk in their decision to have children.  
However, other studies reported that fewer individuals at high risk of having affected 
children made the decision to reproduce compared to low risk women (Hutton & 
Thompson, 1976), and that women at high risk also chose not to have children or 
deliberately delayed having children (Norman et al., 1989).  The findings of the current 
study did not correlate with the above.  The results showed that individuals in the High risk 
group were more likely to have children than the Low risk group.  This suggests that risk is 
not the ultimate deciding factor when it comes to reproduction and that other demographic 
and/or psychosocial influences can contribute to the decision making process.  Two of the 
most important predictors of reproductive decisions are 1) experience with an affected 
individual, and 2) the desire to have children (Weil, 2000).  Studies have shown that 
individuals who intended to have children prior to genetic counselling were nearly 29 
times more likely to have children after genetic counselling than those individuals who did 
not have the intention or who were unsure of their reproductive plans (Weil, 2000). 
 
Eggers, et al. (1999) found that the sisters of affected individuals did not behave differently 
in their reproductive decisions compared to their aunts, cousins and more distantly related 
family members.  In contrast, the current study showed that sisters of DMD/ BMD affected 
individuals were less likely to have children than the aunts of affected individuals (result 
significant) but more likely to have children than their cousins and more distant relatives 
(results not significant).  It was previously shown that reproductive behaviours are strongly 
linked with an individual‟s experience with an affected person or their sense of disease 
burden (Sawyer et al., 2006).  One can surmise that sisters had more experience with the 
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everyday reality of the condition and were therefore less likely to reproduce than the more 
distant aunts.  Even after multivariate logistic regression (Table 3.6, p55) where all 
influential factors were taken into account, relationship to the affected individual was still 
significantly linked to the decision to have children (χ2=169.94).  
 
As expected, the results show that individuals from families with de novo mutations were 
more likely to have children than individuals with previous affected individuals in their 
families.  The researcher thinks it probable that most individuals in de novo families did 
not know about their potential carrier risk, did not have previous experience with affected 
individuals or were most likely not aware of the disease burden.  This is supported by Zatz 
(1983) who reported that risk communication was especially poor in families with de novo 
mutations.  Also, Tedgård, et al. (1999) reported that individuals with a family history of 
haemophilia were more likely to have children in later life.  In addition, studies on at-risk 
haemophilia carriers (Kadir et al., 2000) and confirmed CF carriers (Henneman et al., 
2001) reported that a large proportion of individuals chose not to have children/have 
further children, and that their decisions were mainly influenced by not wanting to pass on 
the defective gene, not wanting to terminate an affected pregnancy and having previous 
experience with an affected individual.  
 
Other factors that were shown to influence the decision to have children were ethnicity and 
age.  The results from this study showed that Black individuals were twice as likely to 
have children and the White individuals were twice less likely to have children when they 
were both compared to Indian individuals.  The multiple logistic regression results (Table 
3.6, p55) showed that Black individuals were still more likely to have children.  The result 
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was not significant (P=0.058) but the researcher believes this would become significant 
with an increase in sample size and shows that ethnicity certainly plays a role in 
reproductive decisions in the South African context.  This can also be justified by Statistics 
South Africa‟s 2006 mid-year census, that showed the fertility rate of Black females to be 
2.92 children per women per year, the fertility rate for Whites, 1.73, and for Indians 1.88 
(Statistics South Africa., 2006).  The results also showed that younger individuals (15 – 25 
years) were less likely to reproduce than the older individuals (36 – 49 years).    
 
4.8 Reproductive behaviour of at-risk individuals who knew about their 
potential risk 
In section 4.7, it was discussed that individuals in the High risk group were more likely to 
have children than individuals in the Low risk group.  The result also showed that 
individuals in the Intermediate risk group were less likely to have children than the Low 
risk group individuals.  These results did not correlate with other studies and the researcher 
questioned whether if one knew the potential carrier risk, whether this might affect 
decisions around reproduction.  Of the 237 individuals in the study, knowledge about 46 
individuals who were aware of their potential risk was available (Figure 3.11, p60).  More 
individuals in the High risk group that were aware of their potential carrier risks chose to 
have children than the Low risk group.  The difference however, was that more of the High 
risk individuals who chose to have children, elected to have prenatal testing compared to 
the Low risk group.  The decision to have prenatal testing depends on the presence of a 
family history and the individual‟s belief about termination of pregnancy.  Individuals in 
favour of termination of an affected pregnancy are more likely to have prenatal testing 
(Tedgård et al., 1999).  The researcher could not comment on the individuals‟ decisions to 
terminate a pregnancy because of the limited information available.   
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4.9 Limitations of this study 
The study was a retrospective, file based study and only the information documented in the 
genetic counselling files could be used for the study.  This resulted in a number of 
limitations; 
 Pedigrees were not always constructed as a three generational pedigree and 
information mostly on the more distant relatives were inaccurate or incomplete.  The 
pedigrees contained a lot of information on the mothers, sisters and aunts of 
individuals but decreased with an increase in relationship distance.   
 Only 116 individuals of the 237 had documented ages which created a great 
restriction in the multivariate logistic regression analysis of the data.   
 Another limitation to the sample size was that 9 files could not be found and 7 files 
lacked all the required information.   
 The study focussed only on families seen in the Division of Human Genetics at the 
NHLS/WITS.  Some of the at-risk individuals could have been seen at other centres 
in South Africa.  This is evident from the demographic results that described the 
ethnicities of the at-risk individuals.  Although DMD/BMD affects all ethnic groups 
similarly, no individuals from the Coloured population have been seen at the genetic 
counselling clinics held from 1995 to 2008, by the Division of Human Genetics, 
NHLS/WITS.  The ethnic groups in this study were thus not representative of the 
South African population.  
 The information in the reproduction section was difficult to obtain from the genetic 
counselling files;  
 It was difficult to deduce from the counselling file whether individuals had affected 
children because some children were younger than the age of onset for 
DMD/BMD.  
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 Limited information was available on whether individuals were aware of their 
carrier risks and were mostly available for the at-risk individuals that attended GC.  
 Limited information was available on decisions to have more children, prenatal 
testing, attitudes about termination of pregnancy, and the pregnancy outcomes as 
the decisions and outcomes were not always followed up.   
 A retrospective study in nature is static and can only record decisions made up to a 
certain point in time.  This is a limitation as one would not know what individuals 
may have decided after receiving genetic counselling, i.e. after receiving their risks, 
information about the disease, testing and reproductive options.  It is known that 
decisions about reproductive choices are usually dynamic (Sawyer et al., 2006) and 
change either with new information that becomes available or with the coping 
strategies of the at-risk individuals and their partners.   
 
4.10 Future recommendations  
 The researcher proposes that more awareness to the public and to the medical 
community should be created with regards to DMD/BMD.  Public awareness can be 
achieved by giving talks to the general community, through radio and television 
interviews, and publishing articles in the Muscular Dystrophy Foundation of South 
Africa magazine, as well as medical and nursing publications. To raise awareness of 
the genetic services in the medical community, talks could be presented especially to 
general practitioners and gynaecologists for CPD points.  These actions may 
contribute to the referral of more at-risk individuals. 
 It is evident from this study that more distant relatives attended less GC and had less 
carrier testing.  A cascade letter could be introduced with the aim to improve 
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knowledge about the familial condition, information about risk and the availability of 
genetic counselling and testing services.  Cascade letters are usually given to the 
individuals that attend GC, and they are asked to forward the letter to their at-risk 
relatives.  
 Individuals that attended GC should be followed up at regular intervals.  The 
researcher feels that continued psychosocial support is important to the at-risk 
individuals, especially when they have to make difficult decisions regarding carrier 
testing, children, prenatal testing and termination of pregnancy.   
 In the time period 1995 to 2008, the South African Institute for Medical Research 
(SAIMR)/NHLS molecular laboratory performed ±526 molecular DMD/BMD tests.  
From the relatively high number of tests performed and the few families seen for GC, 
it can be assumed that either individuals and/or doctors are not aware of the GC 
service provided by the Division of Human Genetics, NHLS/WITS, doctors chose 
not to refer individuals or individuals were referred but chose not to attend GC.  It is 
thus recommended that the doctors ordering the tests and the individuals tested 
should be informed and invited to make use of the GC service.  This can be achieved 
by posting information booklets to both doctors and at-risk individuals.    
 
The significant findings of this study and suggestions by the researcher for future research 
will be summarized in Chapter Five.   
76 
 
5.0 CONCLUSION AND FUTURE RESEARCH 
 
The researcher feels that this study revealed important insights pertaining to genetic 
counselling attendance, genetic counselling referral sources, knowledge and awareness 
around GC and testing services.  The study also provided additional understanding into 
what influences individuals‟ decisions regarding genetic counselling, carrier testing and 
reproduction.  
 
Of the 237 at-risk individuals in the study, roughly a third attended GC.  This could be 
contributed to a number of factors for example, poor family communication of the 
information, individuals not knowing that they were at risk, and individuals and/or medical 
specialists being unaware of the availability of services. GC attendance could therefore be 
improved with awareness campaigns to both the public and health sectors as well as an 
improvement in family communication.  
 
Most individuals in this study who attended GC were either referred by neurologists, 
paediatricians or were self-referred.  Individuals also attended GC for reasons regarding 
affected children or where concerns about a child were raised.  Informing gynaecologists 
and GPs about the genetic counselling and testing services, might shift the reasons for 
attendance towards family planning and prevention, rather than concerns about affected 
children.  As many individuals were self-referred, it can be speculated that individuals will 
seek information if they are aware of their risks and that cascade letters might increase the 
number of self-referrals.  
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Very few individuals knew the disease causing mutation in their families.  This could be 
attributed to the limitations of the molecular testing methods used until 2008.  It can be 
expected that the newly introduced, MLPA method will increase the number of mutations 
detected as it is a more efficient and sensitive method and detects mutations in the full 
DMD gene.  Knowing the family specific mutation may also increase the number of 
individuals who would choose to have carrier testing.   
 
The researcher found the following factors influence individuals‟ decisions regarding GC, 
carrier testing and reproduction: 
 Factors found to influence an individual‟s decision to attend GC were reproductive 
risk, relationship to the affected individual, whether the family mutation was de 
novo, and age of the at-risk individual.  Individuals with a high reproductive risk, 
sisters of affected individuals and individuals from de novo families were most likely 
to attend GC.  Younger individuals and aunts were least likely to attend GC.   
 
 Factors found that influenced an individual‟s decision to have carrier testing were 
reproductive risk, relationship to the affected individual, age and whether an 
individual had an affected child.  Individuals with high reproductive risks, sisters of 
affected individuals, individuals between 26 and 35 years of age and individuals with 
affected children were most likely to have carrier testing.  Individuals least likely to 
have carrier testing were those of the Intermediate risk group (10-24%), aunts and 
individuals between 15 and 25 years of age.   
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 Factors found that influenced an individual‟s decision to have children were 
reproductive risk, relationship to the affected individual, whether the family 
mutation was de novo, ethnicity and age.  Individuals in the High risk group, aunts of 
affected individuals, individuals from de novo families and Black individuals were 
most likely to have children.    
 
Using multivariate logistic regression to analyse the combined influence of all the different 
factors on the decisions of at-risk individuals, the researcher found that: 
 The most significant factor in an individual‟s decision to attend GC, was the 
relationship of that individual to the affected individual.   
 The decision to have carrier testing was dependent on the reproductive risk, 
relationship to the affected individual and age. 
 The factor that was the most significant predictor of reproductive decision was 
relationship to the affected individual.   
 
Although reproductive risk plays a significant role in making decisions regarding GC, 
carrier testing and reproduction, relationship to the affected individuals had the most 
significant influence on the decisions of individuals after all the other factors were taken 
into account.   This illustrates the importance of family communication in the field of 
genetic counselling.   
 
A couple of important conclusions of the study and the practical implications thereof are 
discussed below:  
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 The study found that decisions are complex and influenced by numerous factors.  
Decisions regarding GC, carrier testing and reproduction are dynamic and individual. 
The researcher feels strongly that genetic counsellors should provide continued 
support and promote informed decision making.  Genetic counsellors should focus 
on individuals‟ risk perception, coping styles, beliefs, knowledge and experiences to 
get an idea of what affects their decisions.    
 The study also revealed the need for DMD/BMD awareness to the public and 
medical sector and recommendations were discussed in section 4.10, p74.   
 Lastly, this study demonstrated the need to improve risk communication within 
families. The consensus in the genetic counselling field is that individuals who 
attended GC and who received risk and disease information should be responsible for 
conveying the information to the rest of the family and that information should not 
be passed on by the genetic counsellor/clinical geneticist (Gaff et al., 2007).  In the 
systemic review by Gaff, et al. (2007), it was reported that individuals felt it their 
responsibility to inform the family, but they preferred continuous psychosocial 
support from their counsellors to facilitate communication. The authors also 
proposed that there is not a proven approach to improve communication in families 
but that all families require an individual approach.  In summary, genetic counsellors 
can help improve family communication by providing continued psychosocial 
support and to explore the dynamics and communication patterns of individual 
families. The researcher also proposes that it would be ideal if medical doctors ask 
about familial conditions, identify at-risk individuals in the family and inform 
individuals at-risk, and also refer them for genetic counselling.  
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5.1 Future Research  
As discussed in the limitations of this study, a retrospective study is very restricted in the 
amount of information available.  Decision-making around GC, carrier testing and whether 
to have children or not is a complicated, dynamic process that is dependent on a variety of 
factors, of which personal values and beliefs play important roles. This study was based on 
information recorded in GC files and the researcher had no insight into the individual 
decision-making processes and thoughts.  The researcher proposes that a prospective study 
using interviews, should address the qualitative aspect of these issues.  Such a study could 
explore individuals‟ different coping styles, beliefs, thoughts about disease burden, risk 
perception and other psychosocial influences that may influence decisions.  It could also 
focus on a small sample that consists of individuals in the process of planning a family, 
explore individuals‟ decisions at the time of counselling as well as follow-up on GC, 
carrier testing and reproductive behaviour.   (Khurana & Davies, 2003) 
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Appendix B: Data Collection Sheet 
     
        Number assigned to at risk individual 
  
    
        Demographics 
     
        Age of at risk individual 
   
    
        Ethnicity 
    
    
        Family history of DMD/BMD 
    
        Relationship of the at-risk individual to the affected individual Mother   
      
Sister   
      
Aunt   
      
Cousin   
      
Niece   
      
Other   
        Clinical diagnosis in family? 
   
DMD   
      
BMD   
      
Unconfirmed   
        Confirmed with molecular testing? 
  
Yes   
      
No   
        
 
If no, what was the reason for no results?       
        What type of mutation? 
   
Deletion   
      
Duplication   
      
Point mutation   
      
Unknown   
        
        Genetic Counselling 
     
        Did the at-risk individual attend genetic counselling? 
 
Yes   
      
No   
        If yes, What was the reason for attending genetic counselling? Affected boy   
      
Concern about boy   
      
Family planning   
      
Prenatal   
      
Other   
        
 
If other, what was the reason? 
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        If yes, Who referred the at-risk individual? 
  
Self referral   
      
Relative   
      
GP   
      
Gynaecologist   
      
Paediatrician   
      
Other   
        
 
If other, who referred the at-risk individual?       
        
        If yes, How many follow -up genetic counselling sessions did the at-risk individual have?   
        If yes, What was the reason for follow-up consultation Results   
      
Family Planning   
      
Prenatal testing   
      
Postnatal testing   
      
Other   
        
 
If other, what was the reason? 
 
      
        Risks 
      
        How many at-risk individuals in the family? 
 
    
        Is the family mutation de novo? 
  
Yes   
      
No   
        The family pedigree of the at-risk individual 
   
 
              
 
  
     
  
 
  
     
  
 
  
     
  
 
  
     
  
 
  
     
  
 
  
     
  
 
  
     
  
 
  
     
  
 
  
     
  
 
  
     
  
 
  
     
  
 
  
     
  
 
              
        Risk calculation             
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      Assigned carrier risk 
   
    
        Reproductive risk 
    
    
        Carrier testing 
      
        Did the at-risk individual pursue genetic testing? 
 
Yes   
      
No   
        Results obtained? 
    
Yes   
      
No   
        
 
If no, what was the reason for no results?       
        Reproduction 
      
        High, low or intermediate reproductive risk? 
 
High (>25%)   
      
Intermediate (10-
24%)   
      
Low (0-9%)   
        Did the at-risk individual have any children? 
 
Yes   
      
No   
        If yes, how many children did the at-risk individual have? 
 
  
        Does the at-risk individual have affected DMD/BMD children? Yes   
      
No   
        Did the individual know that she was at risk? 
 
Yes   
      
No   
      
Unknown   
        If yes, Did the at-risk individual choose to have/have more children?  Yes   
      
No   
      
Delayed decision   
      
Unknown   
        If yes, Did the at-risk individual pursue antenatal testing? Yes   
      
No   
        Would the at-risk individual terminate an affected pregnancy? Yes   
      
No   
      
Unknown   
        The outcome of the pregnancy? 
  
Affected  boy   
      
Unaffected boy   
      
Daughter   
      
Terminated   
 
